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Allergic and asthmatic disease is highly prevalent in the UK, however current 
treatments such as steroids, although effective in many individuals, only 
relieve disease symptoms, and do not provide long-lasting relief. Allergen 
immunotherapy can provide long-term alleviation of disease symptoms 
however is only effective in a proportion of patients, carries significant risk of 
adverse side effects and needs to be given over a prolonged period of time, 
often several years, for maximal efficacy.  
 
Allergic disease is associated not only with a type 2 adaptive immune 
response, but also impairment of regulatory T cell function. Allergen 
immunotherapy is associated with skewing of allergen-specific Th2 responses 
towards an IL-10 phenotype, suggesting that plasticity of this T cell lineage 
occurs in vivo. Work from our lab has shown that steroids such as 
dexamethasone, although non-specific in action, augment IL-10 synthesis by 
CD4+ T cells, a response that is enhanced by vitamin D. The major focus of 
this thesis was to assess whether established human CD4+ Th2 cell lines 
could be deviated towards an IL-10+ profile by dexamethasone and 1α25-
dihydroxyvitamin D3, and whether these agents might therefore represent 
appropriate adjuvants to boost the antigen-specific effects of immunotherapy. 
Combined drug treatment of established Th2 cell lines increased Foxp3+ 
expression although these cells were not inhibitory in an in vitro assay of 
suppression. In contrast Th2 cells co-cultured with dexamethasone, 1α25-
dihydroxyvitamin D3 and IL-10 over a 2-week period deviated towards an IL-
10+ phenotype as assessed by qPCR and flow cytometry. Analysis of TCR-
Vβ receptor usage suggested this did not represent clonal outgrowth. These 
cells exhibited strong suppression of Th2 cells in vitro, although this was 
unexpectedly not reversed by addition of neutralizing antibodies to IL-10 or 







Analysis of several genes previously identified to be upregulated in freshly 
isolated CD4+ T cells cultured with dexamethasone and 1a25-
dihydroxyvitamin D3 did not reveal comparable expression by Th2-deviated 
IL-10+ T cells. A transcriptional gene expression array was therefore 
performed in order to search for biomarkers of these deviated cells and clues 
as to suppressive mechanisms by which they inhibit Th2 cells proliferation. 
Genes identified to be of interest included PDCD1LG2, BTLA and several 
granzymes. Granzyme expression was subsequently validated by qPCR. 
 
Severe asthma is associated not only with Th2, but also Th17 cells, therefore 
the capacity of 1α25-dihydroxyvitamin D3 and dexamethasone to deviate 
Th17-associated cytokine production was also assessed. Dexamethasone 
failed, and indeed could enhance IL-17A synthesis in cultures of CD4+ T 
cells, which may contribute to severe steroid refractory asthma. 1α25-
dihydroxyvitamin D3 inhibited IL-17A synthesis in a glucocorticoid-
independent manner. 
 
This work demonstrates that calcitriol and dexamethasone can be used in 
vitro to manipulate T cell plasticity to skew effector phenotypes towards more 
regulatory phenotypes. This has the potential to tailor and further develop 
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1.1 T helper cells – phenotypic classification 
 
The adaptive immune system, coordinated by T helper cells, has developed to 
counteract the effects of numerous antigens and microorganisms. These cells 
provide specificity and memory within the immune system, and direct the 
function of cells within both the innate and adaptive immune compartments. 
The functional consequences of T cell activation are largely thought to be 
beneficial directing the host immune response to combat a large array of 
pathogens. However, it can also drive disease pathology when aberrant 
immune responses develop to self-antigens or environmental antigens that do 
not pose a threat to the host. Conversely, failure to mount adequate adaptive 
immune responses can also lead to disease pathology, such as in cancer and 
chronic infection. 
 
The traditional classification of CD4 T helper cell phenotypes, described by 
Mosmann and Coffman, centred on two classes of T helper cells, derived from 
naïve T cells through responses coordinated by antigen presenting cells. 
These cells - Th1 and Th2 cells 1 – were thought to exist in a state of terminal 
differentiation. In all cases the nature of the T cell phenotype that develops is 
strongly influenced by the antigen presenting cell and cytokine and mediators 
within the local milieu2.  
 
Th1 cell development is classically promoted by secretion of IL-12 from APCs. 
The IL-12 receptor stimulus leads to the increased expression of STAT4, 
leading to the increased expression of Th1 associated genes such as IFNγ. 
TCR stimulus in this setting will lead to increased expression of the 
transcription factor Tbet (Figure 1.1). A prominent consequence of IFNγ 
production is to stimulate macrophages and direct them to intracellular killing 
of pathogens such as viruses and mycobacteria.  
  
Th2 cell development is fostered by the cytokine IL-4, with increased 
expression of the master transcription factor GATA3, and an additional 






involved in the immune response, leading to production of the cytokines IL-4, 
IL-5 and IL-133. Classically the Th2 response has been directed towards 
action against helminths but may be misdirected against allergens (see later 
text). Th2 cells also contribute to B cell help within the immune response. 
 
More recently other classes of T helper cell have been identified that are 
involved in effector responses – these include Th17 cells, Th22 cells, Th9 
cells and T follicular cells (Figure 1.1).  
 
Cells have been identified that predominantly secrete IL-17 and IL-22, Th17 
cells, with transcription factor RORyt (RORC in humans)4. These cells may 
contribute to the pathological response once attributed to Th1 cells and 
mediate diseases such as colitis, arthritis and multiple sclerosis5. In the 
mouse, Th17 differentiation is mainly stimulated by TGF beta and IL-6 6,7. 
These cells may be downregulated by Th1 and Th2 cytokines8 Pathogenic 
phenotypes in humans are driven by the production of IL1β and IL-239 .Th17 
and Th22 cells are predominantly directed towards bacteria and fungal 
pathogens at mucosal sites such as the airways10,11. 
 
Follicular T helper cells have recently been described. These cells have a 
specific predilection for lymphoid follicles and they are required for germinal 
centre development and function, facilitating B cell affinity maturation12. They 
do not have a canonical cytokine to promote development, unlike Th1 and 
Th2 cells that are stimulated by IL-12 and IL-4 respectively. Early 
differentiation is promoted by IL-6 (IL-21 in humans), IL-2 and ICOS and 
depends on TCR signal strength, and development appears to be driven by 
the master transcription factor BCL-613. 
 
The production of Th9 cells is another recently recognised phenomenon, Th2 
cell development in the presence of the cytokines IL-4 and TGFβ may result in 












Most recently, a new phenotype of cells has been identified that secrete the 
cytokines assigned to the T helper cytokine subsets, but do not have cell 
surface markers associated with other immune lineages. These cells do not 
express a T cell receptor. These cells are called ILC cells or innate lymphoid 
cells. They are found in the blood, lymphoid and lung tissue in the mouse and 
they have been identified in BAL fluid and lung parenchyma in humans 16,17. 
ILCs arise from common lymphoid progenitors in the bone marrow, and 
require the transcriptional inhibitor Id2 for their development. The cells 
develop into an ILC precursor that is dependent on the transcription factor 
PZLF. The cells will develop further into more defined lineages – ILC1 (type 
1), that secretes IFNγ, ILC2 (type 2) that secretes IL-6, IL-13 and IL-5, and 
ILC3 (type 17) that secrete IL-22 and IL-17. Broadly the cells function against 
similar pathogens noted for the classical T helper subsets (bacteria/viruses for 
type I, helminths/worms for type 2, and fungi/bacteria for type 17), and by 
implication where the cytokine production of these cells is aberrant, they may 






a growing area of interest is whether ILC2 play a role in the pathology of 
asthma and other allergic diseases18-20. 
 
Intriguingly, the discovery of a larger number of subsets of CD4 effector T 
cells than were first described may reflect increasing plasticity of T cell 
phenotypes rather than final differentiation 21,22. 
 
 
1.2 Regulatory T cells 
 
Recent developments in immunology suggest that CD4+ T cells can 
differentiate into a broader repertoire of phenotypes, which include cells with a 
suppressive phenotype as well as effector phenotypes, with cytokine profiles 
that differ from the previously established dual model of Th1 versus Th2 
effector cell phenotypes. They can be broadly categorised into natural Treg 
and peripheral, or induced Treg23. The ontogeny of regulatory T cells, 
particularly those derived from the periphery, is still uncertain, but they may 
derive from naïve T cells for which thymically derived natural CD4+Foxp3+ 
Treg provides the obvious example, and may also derive from naïve or 




1.2.1 Natural Treg 
 
Sakaguchi identified a subset of T cells originating from the thymus that 
suppressed the immune response.  Knockout (athymic) mice that did not 
express this T cell subset developed catastrophic autoimmunity leading to 
early mortality. The suppressor, or regulatory T cells had high constitutive 
expression of the CD25 marker and this was noted to be an early marker to 
define this cell population24. The Foxp3 transcription factor was later identified 






evidence that knock out of Foxp3 also leads to autoimmunity25. Further 
evidence was provided by the discovery of a severe autoimmune disease in 
humans linked to a mutation in the human Foxp3 gene with a subsequent 
decrease in the regulatory T cell population, leading to an X linked syndrome 
of immune dysregulation, polyendocrinopathy and enteropathy (IPEX) 26. 
 
Thymic Treg cells appear to be a separate lineage from naive T cells that go 
on to become effector T cells upon stimulation. One theory is that a 
subpopulation of cells that have high affinity T cell receptors for self antigen 
express Foxp3 following contact with medullary stromal cells and become 
Treg27. The function of the thymic medullary cells and other thymic accessory 
cells is proposed to allow promiscuous expression of a large array of (self) 
antigens enabling the development of Fox3 Treg with the potential to control 
inappropriate immune reactions28. This process may require the interaction 
between CD154 and CD4029. Other investigators have found that Foxp3 
thymocytes can develop in the cortex even if medullary migration has been 
blocked30.  
 
Maintenance of the Treg pool requires IL-2, for persistence of the phenotype31 
as well as suppressive function through competition for cytokines32. 
Production of new Treg cells may occur in the thymus but thymic involution 
secondary to aging will reduce this number to a very small fraction in adult 
humans.  It is therefore likely that the new nTreg will be sourced from induced 
cells in the periphery.  
 
One problem with phenotypic characterisation has been the specificity of 
CD25 high and Foxp3 as markers for the natural T reg population. These 
markers can be expressed in activated T cell populations33 and therefore 
further attempts have been made to characterise this population in more 
detail. Markers that have been postulated include CTLA 4, GITR and 
CD62L23, but a commonly used combination that does not require cellular 








Expansion of the natural T regulatory cell population is dependent on 
appropriate stimuli from dendritic cells35 and maintained by TGF- β 36. 
 
 
1.2.2 Peripheral Treg 
 
The regulatory T cell repertoire has been further categorised to reflect the 
presence of regulatory T cells that differentiate in peripheral tissues rather 
than the thymus. This may reflect a need to combat harmful immune 
responses that occur as a result of exposure of sites to antigen, with limitation 
of immunopathology37, with natural Treg remaining in situ to combat 
autoimmunity. Both Foxp3+ve38 and Foxp3–ve39 populations have been 
described. Although the cells do not originate in the thymus, they may be 
recent thymic emigrants40. It has been shown that effector T cells in skin 
stimulated through the injection of PPD can be anergised through further 
inoculation with PPD and converted towards a suppressive phenotype 
indicating that Treg can be derived from locally inflamed tissue. IL-10 Treg 
have been described in the periphery, and have been variously proposed to 
be stimulated by IL-1041 , exogenous drugs42 and through stimulation of the 
receptor CD46 43 (reviewed in 44). 
 
1.2.3 Mode of action of regulatory T cells  
 
Regulatory T cells (Treg) can act in a number of ways to suppress effector cell 
function. They can secrete inhibitory cytokines, such as IL-10 or they can 
effect metabolic disruption through cytokine deprivation, e.g. IL-2. They may 
act directly via cytolysis (e.g. via granzymes) or they may act indirectly 



















1.2.4 Stability of regulatory T cells 
 
Treg do not proliferate as strongly as effector T cells in vitro although the 
exact duration of the Treg life cycle is unknown. Persistence of the Treg 
phenotype involves epigenetic modification of Foxp3 – the numbers of these 
cells in the thymus are increased by the use of a histone deacetylase inhibitor, 
and Treg function is enhanced by increased acetylation achieved through the 
nuclear export of histone deacetylase 9 (a class two histone deacetylase) 
which normally binds to foxp3 in resting T cells45.  Methylation is another 
modification that may be significant as it has been shown that natural Tregs 
exhibit demethylation, whereas activated T cells and peripheral TGFβ induced 
Treg do not 46 47. 
 
Most experiments in vitro have derived Treg from naive T cells as described 
above with the addition of specific cytokines such as TGFβ, but the population 
of human RA+ cells in vivo from which the Treg will be derived will be small48. 
nTreg have very short telomeres in comparison to the general CD4+ 
population or memory cell population and therefore it is unlikely that this 
population is generated from a population that replicate indefinitely. This 
raises the possibility that Treg may be generated from proliferating memory 
cells49.  
 
There is evidence of interaction between effector T cell differentiation and 
regulators of Treg. Mantel50 demonstrated that TGF-β mediated Foxp3 
induction is inhibited by overexpression of GATA-3 in a murine model, a 
finding replicated by Wei51 .Wei also found that the Foxp3 induction also 
downregulates the Th1 master regulator T-bet. Reciprocal regulation of Foxp3 
and RORγt/RORC expression has also been identified52.  Expression of 
Foxp3 may have an inhibitory effect on IL-10 expression in asthma38 which 
may indicate different stages of Treg activity during the development of 
aberrant immune responses. The literature indicates that this phenomenon 






immunoregulation at environmental interfaces, whereas Foxp3 is more 




1.3 Asthma and allergy 
 
1.3.1 Epidemiology of asthma and allergy 
 
Allergic disease encompasses a broad range of organ pathology including 
conjunctivitis, rhinitis, atopic dermatitis, food allergy, anaphylaxis and asthma. 
The prevalence of allergic diseases has reached epidemic proportions 
worldwide54,55. The prevalence of asthma alone is 235 million worldwide56. 
Although allergic diseases such as hay fever were noted as far back as 
187055 , the incidence was low. The mid-20th century onwards marked the 
beginning of a sharp escalation in the prevalence and incidence of these 
diseases57, predominantly in Westernised countries. This has led to significant 
morbidity and mortality 58. 
 
The notable increase in allergic diseases over the last 50 years has 
stimulated interest in factors that may have contributed towards modulation of 
immune responses. One major hypothesis that has been postulated is that 
decreased exposure to allergens and antigens in early life may contribute 
towards the development of an allergic response in infancy and beyond. A 
recent paper59 has shown that the introduction of allergen during infancy, 
specifically peanut extract, leads to a decrease in allergic responses to peanut 
at 60 months. Strachan, in his keynote paper60, recognised that there was an 
association between the number of older children in the household and the 
prevalence of hay fever in the first year of life. The increase in atopy persists 
even in later life61. There appears to be an allergic march with age, which 
begins with atopic dermatitis and food allergy, culminating in asthma and 






skew responses away from Th1 towards Th2 responses, at least in affluent 
countries63. In low income countries, where they may be increased exposure 
to parasitic infection, there may be an increase in IgG4 responses, with 
hyporesponsiveness towards antigens64. However, a concept that is 
increasingly being considered is that infectious history may influence the 
frequency of regulatory T cells, based in part on the evidence that not only 
allergic, but also a range of autoimmune, conditions have increased in 
prevalence during a similar time period65.  
 
1.3.2. The Th2 paradigm and evolution into broader phenotypes  
 
The phenotype of allergy is signified by inflammation directed towards a 
harmless allergen. The allergic response is classically divided into two  
phases (figure 1.3) - the early, or acute allergic response (EAR), and the late 
allergic response (LAR). Allergen-specific IgE is bound to the high affinity IgE 
receptor (FCεRI) on mast cells and basophils. Cross linking of IgE by allergen 
leads to mast cell degranulation with resulting discharge of mediators 
including histamine and cysteinyl leukotrienes with instantaneous effects (e.g. 
bronchoconstriction)66. This early phase in asthma is orchestrated by the 
initial secretion of tissue specific cytokines from the airway, namely IL-25, IL-
33 and TSLP67-70. Classically, the late phase is denoted by an influx of Th2 
cells with release of cytokines IL-4, IL-5, IL-9 and IL-13, and also activation 
and degranulation of eosinophils leading to a more sustained response and 
damage of surrounding tissues.   
 
Allergic rhinitis, conjunctivitis and dermatitis broadly fit into the classical Th2 
paradigm in addition to the majority of people with mild allergic asthma71. In 
recent years researchers have noted that the characterization of asthma is 
wider with many more phenotypes of asthma leading to disease, which 
account for the spectrum of severity of the disease and lack of responses to 












Some patients with severe allergic asthma may have a phenotype that 
signifies high IgE production. Other patients will also have a Th2 high 
response, with significant eosinophilia contributing to their disease 
phenotype73. Th2 low phenotypes in asthma might reflect a switch from Th2 
pathways to other effector pathways with a different cellular response 
including Th17 cells, that stimulate antibacterial defences within the mucosa, 
and exhibit a mixed cellular response in the airways with the presence of both 
neutrophil and eosinophil effector response74. 
 
1.3.3 Classical treatments for asthma and allergy – glucocorticoids  
 
The mainstay of treatment for allergic diseases including asthma is 






demonstrated that cortisone had a beneficial effect on asthma75 and other 
allergic diseases76 and over time a broader range of glucocorticoids were 
developed, in both oral and inhaled forms, that could be administered for 
treatment of these conditions77. 
 
1.3.4 Mechanism of action of glucocorticoids 
 
Glucocorticoids are steroid hormones that diffuse through the cell plasma 
membrane and mediate their anti-inflammatory actions via the glucocorticoid 
receptor78. Several variants of the glucocorticoid receptor exist as a 
consequence of alternative splicing. Two main isoforms of glucocorticoid 
receptor have been characterised, GRα and GRβ. GRα is widely distributed. 
In T cells, it is located within the cytoplasm and ligand binding induces 
translocation to the nucleus. . Glucocorticoid receptor complexes formed of 
homodimers of GRα then bind to glucocorticoid receptor elements on genes 
within the target cells, leading to repression of inflammatory pathways, and 
stimulation of others. This broad range of activity enhances the efficacy of its 
anti-inflammatory profile. Negative response elements have been described 
but only a few have been thoroughly characterised. GRβ, on the other hand, 
is predominately nuclear and, in general, is expressed at a lower level than 
GRα within the cell. GRβ is able to bind to DNA but appears to be 
unresponsive to glucocorticoids and the upregulation of this isoform will act as 
a competitive inhibitor of glucocorticoid action78. 
The activated glucocorticoid receptor can also prevent the expression of pro-
inflammatory genes by binding to the RelA and c- Jun subunits of NF-κB and 
AP-1, respectively79. Glucocorticoids are thought to participate in chromatin 
remodelling. Ligand-bound glucocorticoid receptors can recruit histone 
deacetylases, for example HDAC2, leading to a reduction in pro-inflammatory 
gene transcription through the deacetylation of histones80. The actions of the 
glucocorticoid receptor will result in down regulation of transcription factors for 







1.3.5 Glucocorticoid resistance  
 
A proportion of asthmatic patients fail to respond to therapy with 
glucocorticoids, termed steroid resistant individuals. Equally, steroid 
insensitive patients exist, who require high dose, prolonged treatment with 
glucocorticoids to establish clinical efficacy. Approximately 5-10% of patients 
have asthma that is refractory to steroid treatment16. Although this disease 
state is rare, these subjects have major morbidity and mortality81.  
Several theories have been proposed to explain the phenomenon of steroid 
insensitivity. IL-2, IL-4 and IL-13 have all been linked to steroid resistance as 
the expression of these cytokines is elevated in bronchial biopsies of steroid 
resistant asthmatic subjects. IL-2 and IL-4 have been implicated further by in 
vitro studies. For example, this combination of cytokines, acting via p38 MAP 
kinase, phosphorylates glucocorticoid receptors, causing a decrease in 
glucocorticoid binding affinity within the nucleus. Another explanation is that 
the dominant-negative GR isoform GRβ contributes to steroid insensitivity. 
Elevated expression of GRβ has been reported in PBMCs and BAL fluid from 
glucocorticoid resistant, compared with glucocorticoid sensitive asthmatic 
patients82.  
Other risk factors for glucocorticoid insensitivity include cigarette smoking, 
genetic predisposition and allergen exposure. It is probable that multiple 
parameters influence the balance between glucocorticoid 
sensitivity/resistance in asthmatic individuals. Suitable alternative therapies 
are therefore necessary for this important group of patients.  
A number of biological strategies have been developed to identify antibodies 
that block cytokines or receptors involved in the Th2 pathway, as well as IgE 
mediated disease, and more recently TNFα and IL-17. A table of antibodies 











IL-4 and IL-13 IL-4Rα – dupilumab Decreased 
exacerbations of 
asthma and FeNO 
Wenzel S et al, 
201383  
 
IL-13 IL-13 – lebrikizumab Increased FEV1 Corren J et al, 
201184 
IL-4 Mutant IL-4 – pitankira Decreased 
asthmatic response 
Wenzel S et al, 
200785 
IL-13  IL-13 – 
Tralokinumab 
Increased FEV1 Piper E et al, 
201386 
IL-5  Anti-IL-5 mepolizumab Decreased 
exacerbations in 
patients with high 
sputum eosinophils  
Ortega H et al, 
201473 
IL-5 Anti IL-5 reslizumab Decreased 
exacerbations in 
patients in moderate 
to severe 
eosinophilic asthma 
Castro M et al, 
201587 






Laviolette M et al, 
201388 









   
IL-9 Anti IL-9 
enokizumab 









IL-17 Anti IL-17R - 
brodalumab 
 
Moderate to severe 
asthma – no effect 
Busse WW et al, 
201391 




Discontinued due to 
adverse events, 
including one death 
and malignancies 
Wenzel S et al, 
200992 
TSLP Anti TSLP – AMG 157  Reduced FeNO, 
blood and sputum 
eosinophils 
Gavreau et al, 
201493 
 
Successful glucocorticoid therapy is associated with an increase in production 
of the immunomodulatory cytokine IL-10. IL-10 suppresses inflammation 
through reduction of Th2 cytokines and also effects on macrophages and 
dendritic cells44. Steroid resistant patients exhibit a decreased capacity to 
generate IL-10 and strategies to overcome this deficit are advantageous94 
Administration of IL-10 itself is impractical due to its short half-life95, and 
therefore strategies to increase T cell production of IL-10 could prove more 
beneficial. This can be done either through the use of other pharmacological 
agents to augment the IL-10 response, or to increase the number of IL-10 
Treg or Tr1 in the population of T helper cells.  
 
1.3.6. Allergic and asthmatic disease as a sequelae of impaired 
regulation – deficiency or impaired activity of regulatory T cells 
 
Studies have shown that allergic disease states can be associated with a 
decrease in the number and function in the number of nTreg. Ling et al 
demonstrated that patients with hay fever had reduced levels of CD4+CD25+ 
cells with less suppressive capacity during the hay fever season96 a finding 
also demonstrated by Grindebacke in relation to birch pollen97. Hartl showed 






airways of these children, and had decreased suppressor activity98. 
Restoration of immune function can be seen with adoptive transfer of natural 
Treg in mouse models of allergic disease99, and small clinical trials are being 
established to determine the safety of Treg transfer in humans, although 
these trials are being performed within the field of transplantation medicine. 
 
1.3.7 Allergen immunotherapy 
 
In contrast to glucocorticoid therapy, allergen immunotherapy is a more 
specific form of therapy directed at treatment of allergic disease, which may 
have lasting effects after treatment cessation. It is most efficacious in patients 
who have allergic disease mediated by IgE, such as rhinitis, venom 
hypersensitivity and conjunctivitis. Research has indicated that it can be 
effective in asthma but this is not without risk of significant side effects, 
including fatality100 and therefore methods to enhance the safety and efficacy 
of this therapy would be of great benefit to patients.  
The therapy is administered via subcutaneous injections, or more recently the 
sublingual route100 . Regimens involve a prolonged period of administration in 
order to achieve maximal efficacy and immunological desensitisation. 
Therapies exist for the common allergens including grass pollen and bee 
venom, as well as house dust mite101. It is most efficacious if therapy is 
directed against one allergen rather than multiple allergens102. 
Activated T cells play an important role in the immunological mechanisms that 
drive allergen tolerance in the context of allergen immunotherapy. Initial 
theories suggested that successful immunotherapy was stimulated by a 
decrease in IL-4 and IL-5 production by Th2 cells and also a shift toward Th1 
cell production with increased IFNγ103. More importantly in the context of this 
work, allergen immunotherapy stimulates production of IL-10, which is 
predominantly effected through the increased production of Tr1 cells. These 
cells also produce TGFβ103-106. Immunotherapy also reduces the number of 






production of allergen specific IgE from B cells, and increasing the frequency 
of blocking antibodies IgG1, IgG4 and IgA. 
 
 
1.4 Vitamin D  
 
Vitamin D is a secosteroid hormone which plays an important role in bone and 
calcium metabolism107 but it is increasingly recognised that the vitamin has 
immunomodulatory effects that impact on many different systems within the 
body.  
 
Vitamin D can be obtained through two sources: exogenous foodstuffs in the 
diet (e.g. oily fish) with a low yield, but predominantly via conversion of 7 
deoxycholesterol in the skin on reaction with UV light. Vitamin D is converted 
to 25 hydroxyvitamin D in the liver and the last step in conversion towards 
1α,25-dihydroxyvitamin D3, the active form of vitamin D, takes place in the 
kidney, upon the action of CYP27B1. This enzyme is predominantly present in 
the kidney, but also present within immune cells such as macrophages and T 
cells (Figure 1.4). 
 
Vitamin D exerts its effects by binding to the cytosolic vitamin D receptor (a 
member of the nuclear steroid/thyroid hormone receptor family)107 and then 
heterodimerises with receptors of the retinoic X receptor family. The complex 
then translocates to the nucleus where binds to vitamin D response elements 
These elements are present in many target genes and binding will influence 
gene transcription. Binding of the vitamin D complex to response elements 
may be responsible for control of 3% of the genome in mice and humans108.  
 











Studies have shown that there is a widespread level of vitamin D 
deficiency109, particularly in regions that are not exposed to very much 
sunlight, predominantly in countries at the extremes of northern latitude (very 
little production of vitamin D in areas beyond a latitude of 35° in winter110), 
although deficiency may be more widespread due to a global trend towards 
more activity indoors with decreased exposure to sunlight. Countries in 
regions that do have sufficient sun exposure may be affected by the 
requirement for sunscreen to be used in those people who are susceptible to 
skin cancer, which will limit the capacity for UV light to penetrate the skin and 
begin the first step in the conversion pathway towards vitamin D (SPF greater 
than 15 leads to greater than 90% absorption of UVB)111.  In countries with 
high levels of sunshine, cultural and other factors are likely to influence 
vitamin D status and these include dark skin pigmentation, excessive clothing, 
restricted outdoor activity, high levels of atmospheric pollution, and low dietary 







There is increasing interest in the role of vitamin D status and disease. The 
optimal level of vitamin D has yet to be determined112. Severe deficiency in 
children less than 25nmol/l (10ng/ml) will lead to rickets, and in adults will lead 
to osteomalacia. There is, however, increasing evidence to suggest that 
higher levels of vitamin D may be required for optimal bone health and to 
maintain immunological health113. 
 
Epidemiological studies have linked vitamin D deficiency with autoimmune 
diseases such as multiple sclerosis114, in addition to an increased incidence in 
some cancers and also cardiovascular disease107.  Vitamin D status is linked 
to respiratory health, as seen in the Black study115  and there is data 
suggesting that vitamin D deficiency may be related to an increase in 
asthma116.  There is also circumstantial evidence to suggest that vitamin D 
deficiency can be associated with severity of chronic obstructive pulmonary 
disease although this observation may reflect inactivity as a cofounder117. 
COPD and asthma have also been associated with polymorphisms in vitamin 
D binding protein118.  Vitamin D may also play a role in defence against 
infectious disease in respiratory patients119. 
 
The effect of vitamin D in allergy has been controversial. Some authors have 
suggested that vitamin D may enhance Th2 responses in culture120, but 
contrasting evidence has suggested that VDR knockout mice do not develop 
Th2 responses121. While there are the beneficial effects to respiratory health, 
as outlined above, this may be a U shaped curve effect. Researchers have 
noted that IgE levels can be elevated at the extremes of vitamin D 
metabolism. Elevated levels of IgE have been seen at less than <25 nmol/l as 
well as very high levels >135 nmol/l. However, more recent data would 
suggest that restoration of vitamin D levels will help to combat allergic 









1.4.1 Vitamin D and effects on immune function 
 
Vitamin D, through binding to VDR and acting through VDR response 
elements (VDRE) affects a number of pathways in both the innate and 
immune systems. 
  
The active form of vitamin D, calcitriol or 1α,25-dihydroxyvitamin D3, is able to 
act on the innate immune system by downgrading inflammatory responses124 
and augmenting the production of antimicrobial proteins. TLR expression on 
monocytes is downregulated in the presence of calcitriol125. Expression of the 
antimicrobial peptide cathelicidin is increased and the VDRE is noted to 
induce expression of this protein in monocytes, keratinocytes and 
neutrophils125,126. The defensins are also increased following treatment by 
calcitriol127. 
 
Vitamin D can also modulate T lymphocyte function. Many of these effects are 
likely to be mediated by the effects of vitamin D on dendritic cells function  
128. Calcitriol inhibits T cell proliferation and IL-2 production. It has effects on 
Th1 cell cytokines with a decrease in IFNγ production in mice and humans. 
Calcitriol has also been noted to decrease IL-17 production in animal models 
of colitis and uveitis. The situation with Th2 cytokines is slightly more complex 
in that certain studies have shown persistence or enhancement of Th2 
cytokines in vitro and in animal models. This may be due to the 
concentrations used as vitamin D is seen to lower Th2 cytokines at levels of 
10-7 M and below in longer term cultures39,129. Overall, experimental data 
suggesting that vitamin D may enhance Th2 responses is not supported by 
clinical data. Indeed a negative correlation between vitamin D status and IgE 
responses, particularly in paediatric cohorts has been reported122,123. It is 
therefore plausible that additional (Th2-specific?) regulatory mechanisms 
controlled by vitamin D may account for this discrepancy although further 







Work from the Hawrylowicz laboratory that forms the basis of the current 
study includes reports that the use of vitamin D in combination with 
dexamethasone leads to restoration of IL-10 production in steroid resistant 
asthmatic patients131. The combination of the active form of vitamin D3, 
calcitriol, and dexamethasone has been used to deviate naive T cells towards 
a regulatory T cell phenotype with abrogation of Th142 and Th2131 effector 
responses. Vitamin D also promotes a range of immune regulatory functions, 
both innate and adaptive (see Figure 1.5). 
&







1.5 Hypothesis and Aims  
 
The treatment of allergic disease is complex. Current treatments that have a 
broad effect on multiple pathways, such as glucocorticoids, are not allergen 
specific and they are not without morbidity. The development of novel 
treatments has focused on agents directed at single targets (e.g. anti IL-5, anti 
IgE) with variable efficacy in modifying disease. Our increasing knowledge of 
the immunology that underlies these diseases recognises the multiple 
interlinked pathways that contribute to the disease process. Allergen specific 
therapy currently used in the clinic, such as immunotherapy, targets immune 
responses specific for the disease provoking antigen (allergen), but also 
carries risk of morbidity and mortality.  
 
Vitamin D, possibly in concert with dexamethasone, has effects on a number 
of innate and adaptive pathways. Our laboratory has previously described the 
capacity of these agents to promote a regulatory phenotype in peripheral 
blood derived CD4+ T cells.  The studies in this thesis address the novel 
question of whether these mediators also have the capacity to deviate more 
differentiated T effector cell phenotypes implicated in allergic and asthmatic 
disease, towards a regulatory profile, which would enable these cells to act on 
a number of effector pathways in tandem, with potential to facilitate this 
change endogenously in an allergen-specific manner.    
 
Aims  
• Investigate whether established effector Th2 cell lines can be deviated 
in culture towards a regulatory phenotype using vitamin D in the 
absence or presence of dexamethasone and IL-10.  
• Characterise the molecular phenotype of Th2 cells deviated towards a 
regulatory phenotype in order to determine the mode of action of 
regulation.  
• Determine the capacity of vitamin D to alter effector T cell responses 






the capacity of vitamin D to influence the sensitivity of the response to 
















      
     Chapter 2 








2.1 Cell culture 
 
2.1.1 Isolation of peripheral blood mononuclear cells  
 
Ethics approval for this work was obtained from Guy’s Hospital Research 
Ethics Committee (LREC study 1/4/10) and full informed consent was 
obtained from all donors. Donors were aged 18 or over and were either 
healthy or atopic. Atopic individuals were defined by the presence of a 
positive wheal at 15 minutes after skin prick testing to ≥1 of a panel of 
aeroallergens (cat, grass pollen, silver birch, dog, house dust mite, Alternaria, 
Cladosporium and Aspergillus; Soluprick, ALK, Denmark) performed with 
diluent (saline) and histamine controls. Peripheral blood (120 mls) was 
collected from human donors by venepuncture and anticoagulated with 
sodium citrate  (Sigma-Aldrich Co. Ltd, Poole, UK) at a ratio of 10:1 and 
diluted with Hank’s buffered salt solution (HBSS; Life Technologies, 
Gaithsburg, MD) in a 1:1 ratio. Peripheral blood mononuclear cells (PBMC) 
were isolated using a Ficoll density gradient (Lymphoprep®, Axis Shield, 
Oslo, Norway) by layering the blood on the Lymphoprep® at a ratio of 3:1 
followed by centrifugation at 800g for 20 minutes at 18°C. The cells were 
recovered from the interphase and washed twice with HBSS with 2% fetal calf 
serum (FCS; PAA laboratories, Pasching, Austria), first 600g for 10 minutes at 
4°C, then 200g for 10 minutes at 4°C.  
 
2.1.2 Isolation of CD4+ T cells by positive selection using magnetic 
beads 
 
CD4+ T cells were isolated using Dynal CD4 Positive Isolation Kit (Dynal, 
Oslo, Norway). PBMC were incubated with CD4 coated Dynabeads® at a 
bead to target ratio of 3:1 (25µl per 107 PBMC) for 20 minutes at 4°C under 
continuous rotation. The sample was then placed on a magnet for 2 minutes. 
The supernatant containing the CD4+ depleted cells was discarded and the 






the magnet. The bead-bound cells were then resuspended in 500µl of 
2%FCS/HBSS, 200µl of DETACHaBEAD® (Dynal) was added and the cells 
were incubated for 45 minutes at room temperature under continuous rotation. 
The sample was applied to a magnet and the supernatant containing the 
released, purified CD4+ cells was transferred to a fresh tube. The beads were 
washed twice in 2%FCS/HBSS to collect residual cells. The CD4+ cells were 
then washed twice in 2%FCS/HBSS at 200g for 10 minutes at 4°C to remove 
any of trace of the DETACHaBEAD® solution. Purity was routinely assessed 
as >98% by flow cytometry analysis (BD FACSCalibur, figure 1). 
 
2.1.3 Isolation of cell populations by cell sorting 
 
Isolation of CD4+CD45RA+ cells  
 
Human peripheral blood mononuclear cells were isolated as described. The 
cells were counted and then stained with the required combination of sterile 
antibodies at a ratio of 40µl per 108 cells and incubated for 20minutes on ice. 
Labelled antibodies used for sorting were used as follows: FITC CD45RA 
(HI100), PE CD4 (RPA-T4), APC CD45RO (UCHL1), APC-Cy7 CD14 (MΦP9) 
(all antibodies BD Biosciences). 
 
Initial work to adjust compensation involved compensation beads (BD), in 
accordance with the manufacturer’s instructions. In brief 1 drop each of 
negative and positive (anti Mouse IgG) compensation beads (BD) and mixed 
with 100ml of 2% HBSS. Each tube was then incubated with 2µl of a single 
antibody for 20 mins at room temperature. A small aliquot of unstained cells 
was kept as a negative control. 
 
This method was superseded by the use of cells isolated from the PBMCs 
prior to staining, i.e. four individual tubes containing one 2µl aliquot of PBMCs 






as above. This was done to minimise any voltage changes between 
processing beads and using the cell sample. 
 







CD45RA+ cells were isolated from PBMCs using flow cytometry. Purity of the CD45RA+ cells 






2.1.4 T cell culture conditions  
 
Culture of total CD4+ T cells 
 
Isolated cells were counted using a haemocytometer with dead cells excluded 
by the use of Trypan Blue staining. Purified cells were re-suspended at a 
concentration of 1x106cells/ml in RPMI 1640 (Life Technologies), 
supplemented with 10%FCS, 2mM L-glutamine (Life Technologies) and 
50mg/ml gentamycin (Sigma-Aldrich; 10%FCS/RPMI). Cells were stimulated 
with plate-bound anti-CD3 (1mg/ml; clone OKT3; purified in-house) and rIL-2 
(50U/ml; Eurocetus, Harefield, UK). Feeding occurred on day 3; half the 
volume of culture medium was removed and replaced with 10%FCS/RPMI 
with 40U/ml rIL-2.  
 
Generation of human Th2 cell lines in vitro  
 
Purified CD45RA+ cells (1x106/ml) were stimulated with plate-bound anti-CD3 
(1µg/ml; clone OKT3; made in house), anti-CD28 (2µg/ml; clone 15E8; 
Sanquin, Amsterdam, Netherland) and rIL-2 (50U/ml; Chiron, Emeryville, CA). 
rIL-4 (12.5ng/ml; R&D Systems), anti-IFNγ (5µg/ml; clone 7R2/A4; ECACC). 
without or with 5ng/ml IL-10 (R & D) from day 0. Lines were restimulated 
every 7 days. 
 
Cultures were restimulated weekly without (Th2) or with addition of 1α, 25-
dihydroxyvitamin D3 (Biomol) plus dexamethasone (Sigma, both 10-7 M) at 













Total CD4 experiments 
 
Cells were cultured with 1α, 25-dihydroxyvitamin D3 (Biomol) or  
dexamethasone (Sigma, both 10-7 M) at day 0 in some of the total CD4 
experiments. For TLR-2 stimulation experiments, Pam3cys (Invivogen) was 
added to cultures at day 0 at 5µg/ml. 
 
2.2 Identification of Vβ receptor lineage 
 
Th2 cells were cultured without or with 1α, 25-dihydroxyvitamin D3  and 
dexamethasone as above. Cells were then labelled with antibodies from the 
IOTest® Beta Mark kit (Immunotech) in accordance with the manufacturer’s 
instructions. The Vβ receptor lineage was analysed by flow cytometry 
(FACSCalibur, BD). These experiments were kindly performed by Dave 
Richards (Hawrylowicz lab). 
 
2.3 Carboxy-fluorescein diacetate succinimidyl ester (CFSE) labelling 
 
CFSE labelling was performed using Cell Trace CFSE Cell Proliferation from 
Molecular Probes. Cells were washed twice in 1x PBS at 200g for 10 minutes 
at 4ºC and counted.  Cells were labelled with 300µl of CFSE at a final 
concentration of 5mM diluted in 2.7ml PBS per sample, for 7 minutes at room 
temperature. Samples were then washed 3 times in 10% FCS/RPMI at 200g 
for 10 minutes at 4ºC. CFSE staining was confirmed by FACS analysis. 
 
2.4 Functional experiments 
 
Th2 cells were cultured for 28 days, with or without the addition of drugs at 
day 14 of culture. At day 28, cell lines were harvested, washed twice in 
2%FCS HBSS (200g for 10 minutes at 4°C) and resuspended at 1x106 






using magnetic beads (Invitrogen) as previously described and then labelled 
with CFSE dye.   
 
Effector Th2 cells or the putatively deviated Th2 cells (i.e. cells treated with 
calcitriol, dexamethasone and IL-10) were then co-cultured on 96 well plates 
with CFSE-labelled CD4+ T cells at various ratios in the presence of 
autologous APCs (T cell depleted PBMC and αCD3). Cultures were 
performed with or without anti–IL-10 receptor(5µg/ml), anti–TGF-β (5 µg/ml), 
anti-CTLA4 (5µg/ml) (all R&D systems, Abingdon, UK) or isotype control rat 
IgG2a (5µg/ml) (BD Biosciences) . Proliferation was determined by assessing 
the intensity of CFSE signal in the CD4 cells using flow cytometry (BD 
FACSCalibur). 
2.5 Cytokine analysis by intracellular cytokine staining 
 
Cells were fixed using 500µL BD Cytofix® (BD Biosciences) per condition for 
30 minutes on ice followed by a wash (200g for 10 minutes at 4ºC) with 500µL 
1x BD Perm/Wash® (BD Biosciences). Cells were counted and re-suspended 
at 2.5x106cells/ml in Perm/Wash® before staining. 100µl samples 
(2.5x105cells) were stained with specific monoclonal antibodies directly 
conjugated to FITC, PE or APC fluorochromes for 30 minutes at room 
temperature in the dark. The samples were washed with Perm/Wash® 
followed by a second wash with BDFACSFlow® (BD Biosciences) (both at 
200g for 10 minutes at 4ºC). After which, the samples were re-suspended with 
500µL BDFACSFlow®. Matched isotype control antibody staining (BD 
Biosciences) was performed in parallel in each experiment. Samples were 
analysed on a FACSCalibur flow cytometer, following compensation, using 
CellQuest software version 4.0.2 (BD Biosciences). 10,000 live cells were 
analysed for fluorescence based upon forward and side scatter gating. 
Quadrant markers were set according to background staining of matched 







2.6 Cytokine analysis by ELISA  
 
96 well plates were coated overnight with 1µg/ml specific catch antibody in 
bicarbonate buffer [0.1M, pH9.7] at 4ºC. The plates were washed four times 
with PBS buffer [PBS, 0.05% Tween-20 (Sigma-Aldrich). The relevant 
cytokine standards (rIL-5, rIL-10, rIL-13, rIFNγ, R&D systems) were added to 
the plates. Standards were prepared ranging from IL-5 – 20000pg/ml, IL-13 – 
50000pg/ml, IL-10 –10000pg/ml and IFN-γ - 20000pg/ml with serial 1:10 
dilutions in order to titrate a standard curve. The supernatant samples and 
standards in duplicate were also added to the plates, and the plates were 
incubated overnight at 4ºC. The plates were then washed four times in 
PBS/Tween 20 0.05% buffer biotin-labelled detection antibody for the 
appropriate cytokine was added to the individual plate at a concentration of 
1µg/ml in detection buffer [PBS, 0.5% mouse serum (Sigma-Aldrich), 0.5% 
Tween-20, pH 7.4] at room temperature for 2 hours. The plates were washed 
a further four times and then ExtrAvidin® alkaline phosphatase enzyme 
(Sigma-Aldrich) was diluted 1/5000 in detection buffer and added to the plates 
at room temperature for 30mins. The ELISA was performed using matched 
antibody pairs (BD Biosciences; IL-5 (capture clone TRFK5; biotinylated 
detection clone JES-5A10), IL-10 (capture clone JES3-9D7; biotinylated 
detection clone JES3-12G8), IL-13 (capture clone JES10-5A2; biotinylated 
detection clone B69-2) and IFN-γ (capture clone NIB42; biotinylated detection 
clone 4S.B3). The IL-17 and IL-22 matched antibody pairs were obtained by 
using the IL-17 Duoset and IL-17 Duoset kits respectively as per the 
manufacturer’s instructions (R and D systems). 
 
Each plate was washed six times at the end of the ELISA process and 
phospho-nitrophenylphosphate substrate (Sigma-Aldrich) was added at 
1mg/ml in Diethanolamine buffer [0.1M Diethanolamine buffer, pH9.8] to allow 
visualisation of cytokine concentrations. The levels of the individual cytokines 
were measured using a Fusion Plate reader (Packard, UK) at 405nm and 






limits of detection for assay of IL-10, IL-13, IFN-γ, and IL-5 were 50pg/ml, 
100pg/ml, 50pg/ml and 100pg/ml, respectively.  
 
2.7 IL-10 secretion assay 
 
Isolation of live IL-10 secreting cells was performed using an IL-10 Secretion 
Assay Detection Kit (Miltenyl Biotec GmbH, Gladbach, Germany). Cell lines 
were harvested at day 28, washed twice in 2%FCS HBSS and resuspended 
at 1x106 cells/ml in 10%FCS/RPMI. Cells were then restimulated with anti-
CD3 (1µg/ml) and 50U/ml rIL-2 for 16 hours at 37°C/5%CO2. Cells were then 
collected and washed in ice-cold selection buffer [PBS (Life Technologies), 
0.5% FCS, 2mM EDTA (Sigma-Aldrich), pH7.4] at 200g for 10 minutes at 4°C. 
The supernatants from samples were removed by pipetting and cell pellets 
were resuspended in 80µl ice-cold 10%FCS/RPMI per 107 cells. 20µl of IL-10 
catch reagent (Miltenyl Biotec) was added per 107 cells and the samples were 
incubated for 5 minutes on ice. 
After the 5 minute incubation, 10%FCS/RPMI was added to give a cell density 
of 1 x 107 cells/ml and the samples were incubated under continuous rotation 
for 45 minutes at 37°C/5%CO2 to allow secretion of IL-10. Samples were then 
placed briefly on ice and washed in ice–cold selection buffer (200g for 10 
minutes at 4°C). The supernatants from samples were removed by pipetting 
and the cell pellets resuspended in 80µl ice-cold selection buffer per 107 cells 
20µl of PE-conjugated IL-10 antibody was added per 107 cells. Any addition 
staining reagents such as FITC conjugated CD25 (clone M-A251); 10µl per 
107 cells; BD biosciences) were added and the samples incubated on ice for 
10 minutes. Cells were washed for a final time in ice-cold selection buffer and 
resuspended in 2%FCS/HBSS prior to flow cytometry.  
 
2.8 Cytokine bead array analysis of cytokines 
 
ELISA analysis was complemented by the use of the cytokine bead array for 






was used for analysis as per the manufacturer’s instructions. Samples from 
the assay then run on a BD LSR II flow cytometer and quantified using BD 
FCAP array software. The lower limit of detection was 1.5pg/ml. 
2.9 FoxP3 intranuclear staining 
 
FoxP3 staining was performed with a PE- conjugated FoxP3 antibody and the 
FoxP3 staining buffer set, (Ebiosciences, San Diego, USA) according to 
manufacturer’s instructions. Briefly, 1x105 cells were stained for surface 
expression of CD4 and CD25 or the matched isotype control antibody as 
detailed in section 2.6. After which, the cells were washed twice in ice-cold 
FACS flow (200g at 4°C for 5 minutes). The cell pellet was resuspended by 
pulse vortex, 500µl of 1x Fixation/Permeabilisation solution added to each 
sample and incubated for 30 minutes at 4°C in the dark. The samples were 
washed twice in 1x Permeabilisation buffer (1ml; 200g for 5 minutes at 4°C). 
7µl (87.5ng; optimised by titration) of PE- or APC- conjugated FoxP3 antibody 
(clone PCH101) or 87.5ng of rat IgG2a control antibody was added to the 
appropriate tube in 1x Permeabilisation buffer and the samples were 
incubated for 30 minutes at 4°C in the dark. Following two final washes in 
permeabilisation buffer, the cells were resuspended in 250µl FACS flow prior 
to FACS analysis. Quadrant markers were set according to the matched 
isotype control antibody staining. 
 
2.10 IL-13 secretion assay 
 
Isolation of live IL-13 secreting cells was performed using an IL-13 Secretion 
Assay Detection Kit (Miltenyi Biotec GmbH, Gladbach, Germany). CD4+ cells 
from atopic patients were isolated by magnetic bead selection as previously, 
washed twice in 2%FCS/HBSS and resuspended at 1x106 cells/ml in 
10%FCS/RPMI with 5% human serum to minimize background staining. Cells 
were then restimulated with anti-CD3 (1µg/ml) and 50U/ml rIL-2 for 16 hours 
at 37°C/5%CO2. Cells were then labelled with IL-13 catch reagent at 20µL per 
107 cells (5 minutes on ice), and incubated for 45 minutes at 37°C. Cells were 






on ice) and washed with cold buffer. They were resuspended in cold buffer 
and labelled with anti-biotin PE (20µL per 107 cells). Cells were washed again 
in cold buffer and resuspended in 1ml HBSS. Unlabelled cells were used as a 
negative control for compensation. IL-13 PE was added to unlabelled cells 
after the secretion step as a positive control. Cells were labelled with CD4 
FITC antibody (as previously) and sorted according to IL-13 secretion using a 
FACSAria cell sorter (see main text for purity). 
 
2.11. Quantification of mRNA expression  
 
2.11.1 RNA extraction and quantification  
 
Total RNA was isolated from ‘snap frozen’ cell pellets (frozen in liquid nitrogen 
and stored at -80°C) using the Qiagen RnEasy mini kit (Qiagen GmbH, 
Hilden, Germany), according to the manufacturers instructions. RNA was 
treated with Raze-free DBase (Qiagen) before being re-purified using the 
Resay kit and eluted into 30µl of nuclease-free H20. RNA was quantified with 
a Nano Drop ND-1000 spectrophotometer using ND-1000 software version 
3.2.0. The purity and integrity of the RNA was assessed by A260/A280 
spectrophotometric measurements.  
2.11.2 Reverse Transcription  
 
Typically, 250ng RNA was reverse-transcribed into complimentary 
deoxyribonucleic acid (cDNA) in a 30µl reaction. 0.2µg random hexamers 
(Amersham Biosciences, Buckinghamshire, UK) and 250ng RNA were heated 
to 70°C for 5 minutes, and allowed to cool on ice. A master mix containing a 
final concentration of 1x reverse transcriptase reaction buffer (MBI Fermentas, 
Sunderland, UK), 1mM 4dNTP (MBI Fermentas), 20U RNAguard® was added 
to each sample and the reactions were incubated at 25°C for 5 minutes. 200U 
of Revertaid Mouse Moloney Leukaemia Virus (M- MuLV) reverse-
transcriptase enzyme (MBI Fermentas) was added per reaction. The samples 






minutes and held at 4°C. The cDNA generated was stored at -20°C until 
subsequent analysis by Real time RT-PCR. !
2.11.3  Real time RT-PCR  
 
Primer and Probe sets  
Transcriptional expression of target mRNA transcripts were determined by 
PCR amplification, quantified by 5’-nuclease assay using fluorescent labelled 
TaqMan probes and analysed using an ABI PRISM 7900HT Sequence 
Detection System thermal cycler (Applied Biosystems, Foster City, USA). All 
primers/probes sets were purchased from Applied Biosystems. The probes 
have a fluorescently labelled reporter dye, either VIC or FAM that is covalently 
linked to the 5’ -end and a downstream quencher that is not labelled with 
fluorescent dye. The Real time RT-PCRs were internally controlled using 
primers and probes for 18S ribosomal RNA. The 18S probe had a VIC 
reporter dye, whereas all of the other probes had a FAM reporter dye. These 
distinguishable reporter dyes allowed amplification of 18S rRNA and the 
target gene of interest in a multiplex reaction. The RT-PCR was performed in 
a total volume of 10µl per reaction. The Master Mix contained 10ng reverse 
transcribed RNA, 0.5x gene specific probe set and 0.5x 18s probe set and 
each sample was performed in triplicate. The cycle parameters were: 50°C for 
2 minutes; 95°C for 10 minutes for 1 cycle followed by 45 cycles of 95°C for 
15 seconds and 60°C for 1 minute. 
2.11.4 -(ΔΔCt) analysis 
 
For each sample the threshold cycle (Ct) was determined for the target gene 
and the endogenous control (18s), using SDS software version 2.1 (Applied 
Biosystems). The data were first normalised by subtracting the Ct value of the 
endogenous control from the target gene (∆ Ct).  The ∆ Ct of the neutral 
condition sample (control sample) was subtracted from the ∆ Ct of all other 
samples to give ∆ ∆ Ct. Finally, the sample mRNA abundance was calculated 








2.2. Exon ST microarray analysis 
 
Experiments for the Exon ST microarray analysis were kindly performed with 
the assistance of the KCL Genomics centre, Waterloo.  
 
mRNA extracted from the Th2 cell lines and deviated cell lines of interest 
(extracted as described above) were analysed for RNA integrity using the 
bioanalyser and also quantified using the nanodrop. Samples listed were as 
follows. See main text for RNA analysis.  
 
Table 2 mRNA samples for exonST microarray 
Sample no Experiment 
no 
Condition Day of culture 
prior to isolation 
1 34 Th2  21 
2 70 Th2 VDIL-10 28 
3 34 Th2 IL-10 28 
4 34 Th2 IL-10 28 
5 34 Th2 VD 28 
6 34 Th2  28 
7 70 Th2 28 
8 70 Th2 21 
9 70 Th2 VD 28 
10 70 Th2 IL-10 28 
11 69 Th2 IL-10 28 
12 37 Th2 VD 28 
13 37 Th2 IL-10 28 
14 37 Th2 VDIL-10 28 
15 37 Th2  28 
16 69 Th2 21 
17 69 Th2 VD 28 
18 69 Th2 28 
19 69 Th2 VDIL-10 28 
 
3 samples from 4 different cell lines were pooled to represent appropriate 
conditions with a 5th set used to facilitate normalisation (d21 samples). cRNA 
and cDNA was prepared from the samples using the Ambion® WT 
Expression Kit (Affymetrix, CA) and the cDNA was subsequently fragmented, 






GeneChip WT Terminal Labeling Kit (Affymetrix, CA). One exon ST cell chip 
was used for each condition. 
 
Analysis of the Exon ST gene chip array was performed using the Affymetrix 
Expression Console Software analysis to generate mean intensity values after 
normalisation and broadly assess fold changes between cells. It was not 
possible to do further computational analysis due to pooling of the samples.  
 
2.3.  Statistical Analysis 
 
Statistical analysis was performed using Prism 5 for Mac OS X. Data are 
represented as arithmetic means ± standard error means (SEM). A student’s t 
test was used to test the Null Hypothesis and determine differences between 
two sets of data. One-Way ANOVA was used to compare more than two 






































The Th2 cell is a pivotal cell in the pathogenesis of allergic airway disease133 
characterised by expression of the transcription factor GATA3134 and 
secretion of the cytokines IL-4, IL-13 and IL-571. The majority of treatments 
aimed at decreasing the allergic response have been devised with the aim of 
blocking or counteracting further production of Th2 related effector cytokines 
and their associated pathological effects. Patients with asthma have 
previously been categorised into Th2 high or Th2 low subtypes, with a Th2 
high phenotype denoting eosinophilia and steroid sensitivity in some cases. 
There remains a substantial proportion that does not exhibit complete 
responsiveness to this treatment with resultant morbidity and mortality. 
Further work on phenotypes suggests that Th17 cells may coexist with Th2 
cells and promote disease progression. 
 
Strategies to target the effects of pathogenic effector cytokines may involve 
directly blocking or reducing levels of the effector cytokine(s) as outlined 
above. Conversely, an alternative strategy would involve indirect methods of 
blocking the pathogenic response by increasing the number of cells or 
cytokines that will counteract the effector response. Regulatory T cells could 
provide this counterbalance. 
 
Patients with allergic disease are known to have deficiencies in their natural 
Foxp3+ T reg profile98, which can inhibit via various immune mechanisms 
including inhibitory receptors such as CTLA4, competition for essential growth 
factors and inhibitory cytokines and TGFβ23. In addition, Foxp3- T cells 
secreting the anti-inflammatory cytokine IL-10, also appear impaired135 in 
patients. Allergen-reactive CD4+ IL-10-secreting T cells have been shown to 
be present in higher frequencies in cultures from non-allergic as compared to 
allergic individuals (who have higher frequencies of allergen-responsive IL-4+ 
T cells)136. Therefore strategies that will enhance IL-10 levels and peripherally 
induced IL-10 Treg function are generally perceived to be advantageous137.  






enhancing this cell population, but this work is at a relatively early stage, 
impractical for the treatment of allergic disease and not yet ready for the 
clinic138. Recent evidence suggests that the Th1 and Th2 phenotype may not 
represent terminal states of T cell differentiation21. Th2 cells have the capacity 
to change phenotype to produce non-Th2 effector cytokines, but there is also 
evidence to suggest that a variety of CD4+ T cells with an effector phenotype 
have the capacity to express IL-10, which can damp down the initial effector 
response139. Furthermore, this phenomenon may lead to the development of 
tolerance, and also represent the transformation of effector cells towards 
regulatory cell phenotypes.  
 
There is evidence that this phenomenon of tolerance occurs naturally in 
subjects who are tolerant to antigens as a result of natural exposure; bee-
keepers who undergo repeated exposure to bee sting venom develop 
decreased early systemic responses to the allergen, associated with 
decreased frequency of phospholipase-A specific IL-4+ CD4+ T cells and an 
increase in phospholipase-A specific IL-10+ CD4+ T cells140. Tolerance may 
also be achieved through administration of immunotherapy, by suppression of 
Th2 responses and promotion of regulatory cell responses141. Redirection of 
responses in these cases appears to be associated with IL-10 production.  
 
Stimulation of freshly isolated peripheral blood CD4+ T cells together with the 
active form of vitamin D, calcitriol, and dexamethasone, has been shown to 
increase the frequency of IL-10+ T cells in vitro, both in mice and in humans 
42,131,142. The secretion and action of IL-10 is enhanced by the addition of 












Effector Th2 cells can be deviated towards a regulatory phenotype using the 
active form of vitamin D, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3, or 
calcitriol) and dexamethasone in culture. Furthermore, the phenotype of the 
regulatory cells will be comparable to previously described IL-10+ Tr1 T 





• To establish a culture system to reproducibly generate human Th2 cell 
lines 
 
• To use this methodology to investigate the immunomodulatory effects 
of calcitriol, dexamethasone, and IL-10 to deviate this Th2 response 
towards an immunoregulatory IL-10+ Tr1 profile, assess the function of 
the deviated cells in a standard in vitro immune suppression assay, 
and assess the phenotype of cells for expression of Th2 and Treg 

















3.2.1 Generation of effector Th2 cell lines from peripheral blood naïve 
CD4+ T cells  
 
Cell lines were generated using a modified departmental protocol143 utilising 
naïve CD4+ T cells isolated from peripheral blood mononuclear cells (Figure 
3.1). The protocol involved TCR stimulation with anti-CD3 and co-stimulation 
with anti-CD28 without the use of antigen presenting cells. Th1 responses 
were blocked by the use of anti-IL-12 in the first week, followed by continued 
culture in the presence of an anti-IFNγ antibody. Th2 responses were 
promoted by the use of IL-4. An anti-IL-10 antibody was not used in the 
modified protocol as IL-10 production needed to be assessed both in the cell 
line and the deviated cells. Cell lines were restimulated weekly with anti-CD3 
and anti-CD28.  IL-2 was present throughout the whole duration of the culture. 
 
The Th2 phenotype was assessed using intracellular cytokine staining. A 
representative plot of the cell line is shown (Figure 3.2A) with analysis 
performed after three rounds of stimulation, i.e. on day 28 of culture.  PMA 
and ionomycin stimulation of the T cell lines for 2 hours prior to intracellular 
cytokine staining induced a high frequency of IL-13 positive cells when 
analysed by flow cytometry. In this example almost 60% of cells were IL-13 
positive, whilst 23% of cells stained IL-5 positive. This was confirmed on 
analysis of mean data for cytokine production in 3 individual experiments 
(Figure 3.2B). Reassuringly, there was a low level of IFNγ detected after 
repeated rounds of stimulation (Figure 3.2A and data not shown), 


































Figure&3.2A&Flow&cytometry&analysis&of&Th2&cell&lines. Please refer to figure 3.1 and materials and 
methods for the protocol. Intracellular cytokine staining confirmed the Th2 phenotype of the 
cell line, demonstrating a high frequency of IL-13 and IL-5 positive T cells, and a low 
frequency of IFN positive and IL-10 positive T cells by day 28 of culture. 
 
Figure& 3.2B& Mean& cytokine& production& of& Th2& cell& lines. Th2 cell lines were cultured as per 
protocol in fig A and intracellular cytokine staining was performed as above. Mean cytokine 



















3.2.2  Deviation of effector Th2 cells towards a regulatory phenotype 
occurs in the presence of 1α,25[OH]2 vitamin D3 and dexamethasone 
 
Previous work performed by this laboratory group has demonstrated the 
capacity of calcitriol and dexamethasone to deviate CD4 cell lines towards an 
IL-10+ve Treg phenotype131.  The Th2 cell lines that were established in this 
set of experiments were further interrogated by the addition of calcitriol and 
dexamethasone, to establish if the effector cell lines could be deviated away 
from the effector phenotype. Calcitriol and dexamethasone were both added 
at a dose of 10-7 M as this has been shown to promote high levels of IL-10 
secretion in freshly isolated peripheral blood CD4 cell cultures based on 
extensive earlier work in our lab39,42,131. Cell lines were cultured with and 
without exogenous IL-1042 at different doses from day 0 of culture (Figure 3.1) 
to assess any interaction or modification of response. The drugs calcitriol and 
dexamethasone were initially added at 7 days after the commencement of 
Th2 cultures, for the pilot set of experiments. 
 
The deviated cells were assessed for cytokine production via intracellular 
cytokine staining (Figure 3.2). IL-13 production was diminished in the 
presence of either calcitriol or dexamethasone when added as single drugs 
(data not shown), but the reduction was most profound and reproducible with 
the combination of calcitriol and dexamethasone. This effect was 
strengthened by culture in the presence of IL-10 (Figures 3.3 and 3.4). This 
effect persisted through several rounds of stimulation in the continued 
presence of the drugs in culture. This was seen even with the addition of 
drugs at later time points (Figure 3.4 and 3.5). 
 
Further deviation experiments were performed using drugs added at d14 so 
that a putatively more differentiated Th2 cell line had been established. 
Analysis of deviation at this time point corroborated the previous observation 
that Th2 cytokine production was diminished after addition of the drugs 
(Figure 3.4). Interestingly, and unexpectedly, IL-10 production did not 






dexamethasone alone. Significant levels of IL-10 production (by intracellular 
cytokine staining) were seen with the addition of exogenous IL-10 to the 
deviation cultures, in association with abrogation of IL-13 production (Figure 
3.4). This finding contrasts with experiments involving culture of freshly 
isolated CD4+ T cells where addition of exogenous IL-10 was not required131, 
but concurs with earlier work in animal studies demonstrating a requirement 
for exogenous IL-10 to promote IL-10 production in the presence of calcitriol 
and dexamethasone42. This is likely explained by the loss of IL-10 synthesis 
by Th2 cells as they become more differentiated (see Figure 3.4). 
 
The development of an IL-10 response is not instantaneous and it can take up 
to 14 days to demonstrate appreciable levels of IL-10 in vitro (Figure 3.4). The 
IL-10 production represents true secretion rather than a reflection of the 
exogenous IL-10 added to culture, as the levels demonstrated by CBA and 
intracellular cytokine staining were performed after washing and restimulation 








Naïve CD4+ T cells were restimulated weekly under standard Th2 conditions (Th2), some in the 
presence of IL-10 (Th2 IL-10) or with addition of 1α,25[OH]2 D3 plus dexamethasone (both at 10-7 M) 
from day 7 of culture. The addition of exogenous IL-10 inhibits cytokine production and promotes IL-10 
synthesis. 1α,25(OH)2D3 and dexamethasone deviates Th2 cells with a reduction in Th2 cytokines at 





























Top panel . Naïve CD4+ T cells were restimulated weekly under standard Th2 conditions 
(Th2), some in the presence of IL-10 (Th2 IL-10) or with addition of 1α,25[OH]2 D3 plus 
dexamethasone (both at 10-7 M) from day 14 of culture.  Supernatants were extracted from 
cell culture at day 28 and analysed by cytokine bead array. Figure 3.4A shows an experiment 
from an individual donor (n=1)  
 
Bottom panel. Naïve CD4+ T cells were restimulated weekly under standard Th2 conditions 
(Th2), some in the presence of IL-10 added from day 0 (Th2 IL-10) or with addition of 
1α,25[OH]2 D3 plus dexamethasone (both at 10-7 M) from day 7 of culture.  Figure shows 
mean values of intracellular cytokine staining performed after PMA and ionomycin stimulation 
at day 28. Graph represents mean of 4 experiments with 4 individual donors + SEM. *p<0.05, 














Th2 cells exhibit plasticity towards a regulatory phenotype even after several rounds of differentiation. 
CD4+ cell lines were cultured under Th2 conditions with IL-10 added at d0. Some Th2 cell lines were 
cultured in the presence of 1α,25(OH)2D3, and dexamethasone which was added at different time 
points following the start of the culture from day 7, day 14 or day 21 (indicated on x axis). Cytokine 
profiles were analysed by flow cytometry at the time points indicated in the legend (shown in the top 
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3.2.3 TCR Vβ usage in the cell population does not alter upon deviation 
of the Th2 cells using calcitriol and dexamethasone 
 
Experiments outlined in the results above demonstrated that Th2 cell lines 
can be deviated towards an IL-10+ve phenotype, but it was unclear if this 
represented a single or minor population that was being expanded in culture, 
or a true deviation manifested by polyclonal expansion. An experiment was 
therefore performed to assess the nature of TCR usage of both of the cell 
lines and the deviated population in order to explore this question in more 
detail. Th2 cell lines and Th2 cell lines cultured in the presence of IL-10 were 
subsequently deviated with the addition of drugs from d14 and then cultured 
for a total of 28 days. Cells were isolated at day 28 of culture and their TCR 
Vβ usage was assessed using a special fluorochrome staining kit, enabling 
analysis of Vβ receptor usage by flow cytometry.  
 
Analysis by flow cytometry demonstrated a polyclonal distribution of 
expansion of T cell lines as demonstrated by the wide variety of expression of 
TCR Vβ receptor phenotypes seen in the cell lines at day 28 (Figure 3.6). 
There was no obvious change in Vβ receptor usage between the Th2 cell line 
and the deviated cell line with the same polyclonal spread of Vβ receptor  
usage. This finding indicates that the IL-10+ve cells seen in Figures 2 and 4 
are unlikely to represent the outgrowth of a minor population of IL-10 



















Th2 cells were cultured without or with 1α,25(OH)2D3, D3 and dexamethasone from day 14 of culture.  
The Vβ receptor lineage was analysed by flow cytometry at day 28. Figures represent data from two 
individual donors. 
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3.2.4 Isolation of peripheral blood IL-13+ cells ex vivo and response to 
deviation culture conditions  
 
The initial deviation experiments were performed on cell lines generated from 
peripheral blood cells. To further test the hypothesis that effector Th2 cells 
could be deviated with the drugs, an extension of the experimental design 
was devised to test the concept in a more physiological context, using effector 
cells that have undergone development in vivo rather than extended culture in 
vitro. The experimental design incorporated isolation of IL-13 secreting cells 
that were only briefly stimulated in culture (<24hours), as a surrogate for 
established Th2 cells from a human donor. 
 
PBMCs were isolated from human donors as previously described.  CD4+ T 
cells were isolated using magnetic beads and a live cytokine secretion assay 
was performed to label IL-13 positive cells from freshly isolated peripheral 
CD4+ T cells following stimulation with anti-CD3 and IL-2 overnight only (as 
per manufacturers instructions). IL-13 +ve cells were isolated by FACS sorting 





CD4+ cells were isolated from PBMCs ex vivo and stimulated overnight with αCD3 and IL-2. 
IL-13+ve cells were then isolated by FACS following an IL-13 secretion assay with > 95% IL-






3.2.5  Results of ex vivo isolation and stimulation 
 
The number of cells isolated post sort was small (less than 100,000). Cell 
culture was therefore performed using 96 well plates rather than the 24 well 
plates previously used for the in vitro cell line experiments.  The sorted cells 
were therefore stimulated with anti-CD3, IL-2 and IL-4 every 7 days to allow 
expansion to occur. Cell numbers obtained during the earlier rounds of 
stimulation were too low to enable the cultures to be split (the initial plan had 
been to leave one group of the ex vivo cells for simple restimulation and 
another for deviation).  This change in experimental design meant that 
calcitriol and dexamethasone were not added until day 28. A representative 
plot of the deviation experiments is shown in Figure 3.8.  
 
The percentage of cells that were still positive for IL-13 by intracellular 
cytokine staining at day 28 was approximately 16%, (which may reflect the 
earlier problems with identification of the true IL-13+ve cells in the context of 
non-specific binding, see section 2.10 in Materials and Methods). 
Nevertheless, addition of calcitriol and dexamethasone at day 28 did induce a 
downward trend in the number of IL-13+ve cells (by about half). This did not 
correlate with an increase in IL-10 expression. This probably reflects the fact 
that culture conditions did not include exogenous IL-10.  
 
It was therefore decided that this line of experimental design would not allow 
us to address our original question. Low yields of IL-13+ T cells obtained 
directly ex vivo were insufficient to allow the drugs to be added immediately to 
culture. Expansion of effector cells meant that we were no longer studying an 
ex vivo Th2 cell, and in any case still did not enable sufficient numbers of cells 
for genetic analysis with mRNA. 
 
The remaining experiments were carried out using the Th2 cell lines 














CD4+ cells were isolated from PBMCs ex vivo and stimulated overnight with αCD3 and IL-2. IL-13+ve 
cells were then isolated by FACS following an IL-13 secretion assay > 95% IL-13 purity. Cells were then 
cultured in the presence of IL-2 and IL-4 and restimulated every 7 days with αCD3. 1,25(OH)2D3, and 
dexamethasone were added at d28. Intracellular staining was performed at d35. Figure 
3.8representative of 2 experiments. 
 
3.2.6 Deviated Th2 cells (Th2 IL-10 VD cells) have suppressive function, 
which is not abrogated in the presence of anti IL-10 receptor antibody 
 
The experiments described above demonstrate the capacity of Th2 cell lines 
to undergo deviation towards a putative regulatory cell profile in vitro, with 
persistence of the phenotype for at least 14 days, and no evidence to suggest 
reversion to secretion of the effector cytokines.  Further experiments were 






proliferation of autologous CD4s, and therefore had the potential to inhibit 
inflammatory responses. 
 
Cells were isolated at d28 following 14 days of treatment with drugs. Fresh 
autologous CD4s were also isolated at the same time point and labelled with 
CFSE, a dye that allows analysis of cell proliferation by flow cytometry. The 
freshly isolated CFSE-labelled CD4s were then co-cultured with the cell lines 
at the indicated ratios in the presence of autologous APCs and αCD3.  
 
Proliferation assays demonstrated that the baseline level of proliferation when 
the autologous CD4 cells were stimulated alone with αCD3 plus  autologous 
APCs  was approximately 40%. This level of proliferation was maintained 
when the autologous T cells were co-cultured with Th2 cell lines. As expected, 
the Th2 effector cell lines, when isolated at day 28 and co-cultured with fresh 
autologous CD4s did not demonstrate inhibition of proliferation.  (Figure 3.9).  
When the CD4s were cultured in the presence of the Th2 cells that had been 
deviated with calcitriol, dexamethasone and IL-10 there was suppression of 
proliferation. This suppression was seen with cell ratios as low as 1 
suppressor cell to 16 CD4s (Figure 3.9.). Co-culture of cells deviated with 
vitamin D and dexamethasone alone (i.e. not cultured with exogenous IL-10) 
and autologous CD4s surprisingly did not result in any inhibition of 























Th2 cell lines and deviated T cell lines were assessed by co-culture with autologous, freshly isolated, 
CFSE-labelled CD4+ T cells in the presence of autologous APCs. Top figure, representative CFSE plots 
from one of three experiments showing co-cultures using Th2 cell line and Treg cell line. Cultures were 
performed at varying ratios of deviated (Treg) or effector (Teff) cells to responder CD4 cells (Tresp).  
Bottom figure. Following 72hrs of stimulation, proliferation was assessed by intensity of CFSE signal as 
measured by flow cytometry. Approximately 40% of the CFSE-CD4+ responder T cells proliferated (n=1 
experiment with titration to 1:16 ). Th2 cells deviated by addition of dexamethasone, 1α,25(OH)2D3, and 
IL-10 to culture caused profound inhibition of CD4+ responder T cell proliferation at all ratios tested.  
 






Co-cultures were also performed in the presence of blocking antibodies to 
evaluate if suppression was related to IL-10 synthesised by the deviated Th2 
cells (Th2 VD10), or TGFβ, another suppressive cytokine involved in 
regulatory T cell function. Suppression of proliferation by the drug deviated 
cells was not affected by blockade of TGFβ (Figure 3.10). Surprisingly, 
proliferation of CD4s was not restored by the presence of anti-IL-10 receptor 
antibody either.  There was also no change in proliferation when anti-CTLA 4 
antibody was added to the co-culture, although CTLA4 is increased in freshly 
isolated peripheral blood CD4+ T cells following culture with vitamin D144. 
 
The result of the mean proliferation data for co-cultures performed in the 
presence of anti-IL-10 receptor antibody was unexpected, given that the 
blocking antibody is a reagent that has been previously utilised in the lab both 
before and after these experiments were performed,  (in the context of 
deviation of freshly isolated CD4+ T cells), resulting in restoration of 
proliferation131.  Whilst the efficacy of this reagent was not formally proven 
and therefore remains a caveat in the interpretation of these experiments, this 
appears an unlikely explanation for the findings. The cytokine profiles of the 
cell lines were reviewed and these demonstrated robust IL-10 production in 
the drug-deviated cell lines (Figure 3.4). 
 
In conclusion, the experiments in this chapter show that Th2 cells can be 
deviated towards a regulatory T cell phenotype in the presence of calcitriol 
and dexamethasone, and this requires the additional presence of IL-10 in 
culture. The cell lines expressed high levels of IL-10 as assessed by flow 
cytometry, but this is not the primary mechanism for the suppression. Further 
work described in the subsequent text describes the investigation of 



















Top panel  Cultures were performed at varying ratios of deviated (Treg) or effector (Teff) cells to 
responder CD4 cells (Tresp)n the presence or absence of αTGFβ and αIL-10 receptor antibodies. 
Following 72hrs of stimulation, proliferation was assessed by intensity of CFSE signal as measured by 
flow cytometry.. Figure demonstrates experiment using one individual donor. 
Bottom figure. Mean proliferation of autologous CD4 (Tresp) cells by CFSE staining under different 



























































































3.2.7 Addition of calcitriol and dexamethasone to Th2 cells maintains 
and increases expression of c-maf, but reduces  GATA3 expression 
 
Human CD45RA+ cells were deviated towards a TH2 profile without or with IL-
10 as previously described. Cultures were restimulated weekly without (TH2) 
or with addition of calcitriol plus dexamethasone (both 10-7 M) at day 14. 
mRNA was extracted as described above. Initial experiments investigated 
changes in the mRNA expression of the Th2-associated transcription factors 
c-maf and GATA3, assessed using real time RT-PCR.  
 
Analysis of the RT-PCR data showed that an increase in c-maf was seen in 
the calcitriol/dexamethasone/IL-10 treated cells despite the deviation towards 
an IL-10 Treg cytokine profile (Figure 3.11). The increase in c-maf was 
sustained and persisted until day 28 of culture.  In contrast, GATA3 
expression was reduced in the calcitriol/dexamethasone/IL-10 cells, 
decreasing progressively with time while expression of GATA3 was 











Cells were cultured under Th2 deviating conditions, some in the presence of IL-10  (Th2 IL-10) or with 
addition of 1α,25(OH)2D3, plus dexamethasone (both at 10-7M) from day 14 of culture.  
Cell pellets were obtained at d28 and mRNA was extracted from the cell pellets. Quantitative rR-PCR 
was performed using cDNA created from the mRNA . Data represents mean + SEM of 3 experiments, 3 
different donors, *p<0.05, one way ANOVA 
 
3.2.8 Foxp3 expression is increased in Th2 cells by addition of calcitriol 
and dexamethasone. The increase in Foxp3 expression is abrogated by 
the addition of IL-10  
 
Human CD45RA+ cells were deviated towards a Th2 profile without or with IL-
10 as previously described. Cultures were restimulated weekly without (TH2) 
or with addition of calcitriol plus dexamethasone (both 10-7 M) at day 14.  The 
mRNA expression of Foxp3 was analysed and all conditions were compared 
to Th2 at day 7. Cells treated with calcitriol and dexamethasone alone showed 
an increase in Foxp3 expression in comparison to the Th2 cells. The 
expression was abrogated by the addition of IL-10 to culture (Figure 3.12). 
There was a reciprocal pattern of IL-10 versus Foxp3 mRNA expression, with 
the drug plus IL-10 treated Th2 cells showing significantly higher IL-10 gene 
expression than the control Th2 line. Th2 cells cultured with IL-10 or Th2 cells 
treated with drugs (but no IL-10) were not significantly different in IL-10 mRNA 
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Analyses of these patterns by flow cytometry demonstrated a similar pattern 
of protein expression with elevated levels of Foxp3 seen with the calcitriol and 
dexamethasone treated cells vs the Th2 VD IL-10 cells treated with 























Top figure. Cells were cultured under Th2 deviating conditions, some in the presence of IL-10  (Th2 IL-
10) or with addition of 1α,25[OH]D3 plus dexamethasone (both at 10-7M) from day 14 of culture.  
Cell pellets were obtained at d27 and mRNA was extracted from the cell pellets. Quantitative RT-PCR 
was perfumed using cDNA created from the mRNA. Data represents mean + SEM of 3 experiments, 
one way ANOVA, * p<0.05 
 
Bottom figure.  Cells were cultured under Th2 deviating conditions, some in the presence of IL-10 (Th2 
IL-10) or with addition of 1α,25 [OH] D3 plus dexamethasone (both at 10-7M) from day 14 of culture. 
An IL-10 secretion assay was performed overnight on cells obtained at d28 of culture. Intracellular 
staining was then performed to assess expression of IL-10 and Foxp3. Data represents mean + SEM  of 


















Cells were cultured under Th2 deviating conditions, some in the presence of IL-10 (Th2 IL-10) or with 
addition of 1α,25 [OH] D3 plus dexamethasone (both at 10-7 M) from day 14 of culture. 
An IL-10 secretion assay was performed overnight on cells obtained at d28 of culture. Intracellular 
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The initial experiments described in this chapter confirmed that human Th2 
cell lines can be maintained in vitro after several rounds of differentiation 
without the use of a blocking IL-10 antibody. The cytokine profile of these cell 
lines favoured a Th2 rather than a Th0 phenotype with high levels of IL-13 
and IL-5, and low levels of IFN gamma. IL-10 production was seen initially but 
was transient. The human Th2 cell lines were relatively robust with the 
repetitive stimulus and had a singular Th2 profile without co-expression of 
Th17 as seen by other authors145. 
 
The experiments presented here also demonstrate that calcitriol and 
dexamethasone in combination with IL-10, when added to the Th2 cell line 
cultures, significantly increases the frequency of IL-10+ T cells and reduces 
the IL-13+ T cells, indicative of a more regulatory profile. The capacity for 
deviation exists even late into the Th2 cell differentiation process, occurring as 
late as the addition of drugs 21 days into culture. 
 
 Calcitriol and dexamethasone abrogated production of the Th2 cytokines 
when added to the culture but did not stimulate IL-10 production, which 
required the addition of exogenous IL-10.  This may reflect an endogenous 
requirement for APCs to produce IL-10 in vivo to support skewing towards an 
IL-10 synthesising T cell population35, particularly when calcitriol and 
dexamethasone are used in a milieu of Th2 effector cytokines.   
 
Having established that the drugs could deviate the cell lines, it was important 
to investigate whether this represented true deviation rather than outgrowth of 
a single population. TCR Vβ usage in the Th2 cell line appeared polyclonal as 
would be expected from the mode of stimulation and the pattern did not alter 
upon deviation of the Th2 cells using calcitriol, dexamethasone, and IL-10, 
suggesting the observed results did not represent outgrowth of a minor T cell 
population. However, improved technologies such as newer cell proliferation 






that the lab has used for 2-weeks or longer in culture) would allow additional 
investigation of this issue, for example by combining CellTraceViolet with IL-
13 and IL-10 staining in a time course study. 
 
The generation of IL-10 and reduction of Th2 cytokines signifies a change in 
phenotype but the capacity to regulate and suppress effector responses 
required confirmation in a further set of functional experiments. Cells that 
were deviated in the polyclonal culture demonstrated suppression of 
autologous total CD4s in co-culture, supporting the hypothesis that culture of 
the Th2 cells with the immunosuppressive drugs and cytokine IL-10 leads to a 
regulatory phenotype. This suppression appeared potent as even at a ratio of 
1Treg (deviated Th2 cell) to 16 effector cells there was no recovery of the 
Tresponder proliferative response. This suppression was not reversed in the 
presence of anti-TGF-ß antibody, or albeit in only a single experiment, by a 
CTLA4 inhibitory antibody. Surprisingly IL-10 blocking antibody also did not 
reverse this effect, as might have been expected given the increased 
frequency of IL-10+ cells in the deviated population, and if the regulatory 
effect was mediated by the suppressive cytokine alone. This result was 
unexpected and an important line to pursue would be whether combinations 
of the blocking antibodies used would lead to some recovery of effector T cell 
proliferation. However given that no effect of any of these antibodies was 
observed it is debatable whether this would be the case.  
 
Preliminary investigation of the deviated cells exhibiting suppressive function 
(Th2 VD IL-10) suggested that these cells did not show increased expression 
of Foxp3 and therefore the drugs plus IL-10 were not causing augmentation of 
natural Treg responses. Increased Foxp3 expression was observed in Th2 
cells that had been treated with drugs, but no IL-10, however this cell line did 
not exhibit suppressive activity in the in vitro suppression assay used. It 
therefore seems more likely that the increased Foxp3 expression may be 
more analogous to activation-dependent Foxp3 expression as previously 






here there was reciprocal expression of Foxp3 expression and IL-10 
production, and exogenous IL-10 appeared to prevent Foxp3 expression.  
 
Our lab previously reported a similar pattern of responsiveness in cultures of 
freshly isolated CD4+ T cells stimulated in the presence of calcitriol. Whether 
IL-10 or Foxp3 was preferentially increased in culture was influenced by both 
calcitriol concentration and the cytokine milieu; here also IL-10 had a negative 
effect on Foxp3 expression. However in that system both the IL-10 and 
Foxp3+ T cell populations exhibited comparable suppressive function144 
although the reason and significance of this is unknown.  
 
In the Th2 VD IL-10 deviated cell lines, GATA3 mRNA expression was 
reduced but c-maf expression was maintained and even increased, and this 
may reflect the influence of c-maf on the IL-10 promoter 146. Blockade of the 
AhR (Aryl hydrocarbon receptor) was not tested to see if this affected the 
increase in expression of IL-10 seen in concordance with the increase in cmaf 
expression147. 
 
Whilst the Th2 cell line was robust, it remains an artificial experimental in vitro 
system and it would have been advantageous to achieve a more physiological 
design to the experiments to test the deviation hypothesis. Experiments were 
performed on cells isolated ex vivo to try and achieve a more physiological 
replication of Th2 conditions and results demonstrated the complexity of using 
such an approach. IL-13+ cell numbers after use of the secretion assay were 
low after repeated rounds of stimulation which may reflect the use of 
stimulation with anti-CD3 and IL-2 rather than using anti-CD3 and anti-CD28 
assuming that the effector cells were robust in phenotype. Alternatively a 
decrease in IL-13+ve cells may favour the theory of potential plasticity of the 
Th2 phenotype21. It may have been advisable to use a marker other than the 
cytokine IL-13 to identify Th2 cells. Other authors have suggested the use of 
CRTH2 as a marker for Th2 cells148, but this marker is not specific to Th2 
cells. Combinations of antibodies to detect CRTH2, and certain chemokine 






strategies to improve ex vivo detection of Th2 cells in humans in the future. 
New technologies such as single cell PCR might also enable this type of 
future work where very low cell numbers are available.  
 
Further work leading on from these results would aim to shed further light on 
the robustness and plasticity of the cell lines and the deviated cells, further 
clarification of their phenotype, as well as the mechanism of suppression. 
 
Investigation of stability and plasticity of the Th2 effector cell lines generated 
in vitro would involve withdrawal of the Th2 cytokine stimuli for longer rounds 
of stimulation (as opposed to a brief withdrawal used in the co-culture 
experiments with CFSE at d28). The cell lines would also be tested for ability 
to maintain the Th2 phenotype in other effector conditions by culture in Th1 or 
Th17 conditions.  
 
Further investigation of the deviated, IL-10+ cell phenotype could be done 
using a cell surface approach to delineate further cell surface markers or 
alternatively a molecular approach to define factors leading to an IL-10 Treg 


































Characterising the phenotype of Th2 cells deviated towards a regulatory 









Experiments performed and summarised in the previous chapter described 
the deviation of effector Th2 cell lines towards an IL-10-positive regulatory 
phenotype.  An unexpected finding of the deviation experiments was that the 
regulatory capacity of the cells was not abrogated by the addition of anti IL-10 
receptor antibody to culture, or by the addition of a neutralising antibody 
specific for TGF-β. This result inferred that there are likely to be additional 
mechanisms involved in the suppressive activity of the drug treated cells that 
were not related to the actions of IL-10 or TGF-β. It is uncertain if CTLA4 
contributes to the suppression observed given the single experiment 
performed using an anti-CTLA4 neutralising antibody, where blocking again 
did not restore effector T cell proliferation, and this would need further 
experiments to clarify. These findings may therefore reflect the broader 
repertoire of regulatory T cell action in relation to suppression of effector cell 
function23. The cells deviated in the presence of vitamin D and 
dexamethasone alone in the absence of IL-10 were found to have increased 
expression of the transcription factor Foxp3, the most common marker of 
Treg. Surprisingly, these cells were not inhibitory in a conventional 
suppression assay. Foxp3 expression in this instance is likely to represent T 
cell activation33 rather than a regulatory phenotype,  
 
Preliminary investigation of the phenotype of the regulatory cell lines focused 
on the assessment of transcription factors that have historically been 
associated with T helper cell development. Conventionally the Th1 phenotype 
is promoted by T-bet expression, and GATA-3 expression favours Th2 lineage 
expression with contribution by c-maf.  Interestingly, c-maf is also linked to IL-
10 expression146. The main transcription factor expressed in Th17 cells is 
RORyt (RORC in humans)4. Sakaguchi identified Foxp3 as the pivotal 
transcription factor required for development of natural Treg149; conversely the 
level of expression of this transcription factor in induced Treg populations, 






phenotypes exhibit plasticity dependent on the differential expression and 
interaction of transcription factors. 
 
The lab has previously taken two experimental approaches to investigate 
transcriptional factors and antigens that might be specifically expressed by 
drug induced Treg populations, and which might therefore provide an 
indication as to the developmental origins of these cells, and/or their function. 
In the first approach the scientific literature at the time was reviewed to 
identify likely candidates. This approach lead to the identification of toll like 
receptor (TLR9) as one of the few, if only, genes/molecules to be specifically 
highly expressed by drug-treated CD4+ T cells that had been selected by live 
cytokine secretion assay for IL-10-positivity. Notably, and unexpectedly, 
ligation of this receptor by specific agonist (ODN-CpG) on the calcitriol /dex 
induced IL-10+ Treg lead to decreased IL-10 synthesis and increased IL-4 
levels. The second approach used conventional gene transcriptional arrays, 
performed by Dr Patricia Ozegbe when she was a postdoctoral fellow in the 
lab, on highly differentiated drug-treated CD4+ T cells, again selected for IL-
10-positivity and compared against drug treated IL-10 negative T cells, and 











Effector Th2 cell lines deviated towards a regulatory phenotype with 1α,25 
[OH]2D3, dexamethasone and IL-10 have a specific molecular signature that 
defines them within the subset of induced regulatory T cells. This signature 




To identify genes of interest that represent biomarkers of, or may influence 
the regulatory phenotype, of Th2 cells deviated towards an IL-10+ Treg 
phenotype following addition of calcitriol (vit), dexamethasone (dex) and IL-10 
to the Th2 culture, by: 
 
• Screening by qRT-PCR for the expression of genes of interest 
identified by earlier gene transcriptional arrays performed in our lab on 
drug-treated IL-10+ CD4+ T cells (as opposed to Th2 cell lines) using 
microarray technology, and by candidates identified in the scientific 
literature e.g. TLR22 and TLR99. 
 
• Perform transcriptional gene array analyses on IL-10+ ‘reg generated 
following deviation of Th2 cell lines by the addition of calcitriol, 
dexamethasone and IL-10 to culture, using the methodology optimised 
in the previous chapter. 
 
• Validate the microarray analysis by confirming the mRNA expression of 
genes of interest.  
 
• If pathways identified, explore the effect of blocking the pathways on 










4.2.1 Genes regulating innate immunity are not upregulated in deviated 
regulatory Th2 cells cultured with 1α,25 [OH]2D3, dexamethasone and 
IL-10 
  
A microarray that had previously been performed by the Hawrylowicz lab (Dr 
Patricia Ozegbe) on total (naïve and memory) peripheral blood derived CD4 T 
cells treated with 1α,25[OH]2D3 and dexamethasone (without prior culture in 
Th2 deviation conditions) was initially used to identify potential genes of 
interest in the Th2 deviated cell population. Cells cultured in this experimental 
protocol131 demonstrated upregulation of a number of genes in the IL-10 
positive cells in comparison to the IL-10 negative population (Ozegbe & 
Hawrylowicz, unpublished). In addition expression of certain TLR by the same 
cells was identified in a separate study by Dr Zoe Urry, following a review of 
the relevant scientific literature39. These upregulated genes were primarily 
associated with the innate immune response  (Table 1) and this preliminary 
list suggested avenues for further investigation of the regulatory T cell 
phenotype. Upregulated genes included the toll like receptors TLR2 and 
TLR9, an effect strongly linked to the effects of vitamin D although ligation of 



















Table 3 Upregulated genes Ozegbe microarray 
 
 Function 
SERPINA1   Serine Protease inhibitor150, encoding for the 
protein alpha1 antitrypsin  
TENASCIN C Extracellular matrix glycoprotein151 
TIMP 2 Tissue inhibitor of metalloproteinase152 
CLEC 7A Non-toll-like pattern recognition receptor153 
TLR 2 Toll like pattern recognition receptor154 
TLR 9 Toll like pattern recognition receptor39 




4.2.2. Analysis of TLR2, TLR9 and SERPINA1 mRNA expression 
 
Earlier work in our lab demonstrated upregulation of TLR9 in drug induced IL-
10+ Treg, which was one of the few genes associated with an IL-10+ 
phenotype39. There was also upregulation of TLR-2, which has been 
associated with regulatory responses154. SERPINA, which codes for the 
protein alpha 1 antitrypsin, a serine protease inhibitor, was also upregulated  - 
notably, there is evidence that inhibition of serine protease activity may be 
involved in Th2 responses156; and alpha 1 antitrypsin has been reported to 
increase IL-10 synthesis by monocytes157. 
 
Experiments to analyse the phenotype of the deviated Th2 cells assessed the 
mRNA expression of the above genes as shown in table 4.1 in the effector 
(Th2) and deviated (Th2VDIL-10) cell lines. Th2 cell lines were cultured for a 
total of 28 days with 1α,25 [OH]2D3 and dexamethasone added at either day 






isolated from cell pellets at various time points indicated and reverse-
transcribed to create cDNA. mRNA expression was determined by PCR 
amplification and quantification.  
 
TLR9 mRNA expression did not change significantly in cells treated with the 
1α,25 [OH]2D3 and dexamethasone alone by day 14 (after 7 days of culture 
with drugs). By day 21 there was a modest increase in TLR9 expression 
(Figure 1) in one of the two donors studied, and observed only with the full 
combination of 1α,25 [OH]2D3, dexamethasone and IL-10.  
 
TLR2 expression was increased in cells cultured in the Th2 cell lines (Figure 
4.1) in both donors tested. However there was no convincing change in 
expression with the addition of IL-10, 1α,25 [OH]D3 and dexamethasone, or 
1α,25 [OH]2D3 and dexamethasone plus IL-10.  
 
Analysis of expression of the SERPINA1 gene in the deviated Th2 cell lines 
showed consistent results between the two donors. In comparison to the T 
cell lineage generated under Dr Patricia Ozegbe, there was downregulation 
and decreased mRNA expression in the deviated cell line cultured with 1,25 
[OH]2D3, dexamethasone and IL-10 (Figure 4.2). 
 
Gene expression of IGF1 increased under all culture conditions with time, and 
was highest in cells treated with 1α,25 [OH]D3 and dexamethasone, with the 
highest levels of expression seen with the addition of IL-10 (Figure 4.3) in 
both donors. This increase in IGF1 was not explored further as analysis was 
superseded by the new microarray (see below). It may reflect an increase in 
genes related to tissue repair, as demonstrated by the increase in tenascin 


















Cells were cultured under Th2 deviating conditions (th2), some in the presence of IL-10 (IL-
10), or with addition of 1α,25 [OH]D3 (v) and dexamethasone (d; both at 10-7M) from day 7 of 
culture Cell pellets were obtained at d21 and mRNA was extracted for analysis. Quantitative 
RT–PCR was performed using cDNA created from the mRNA. Th2 cell lines or deviated cells 
were compared to pellets from d14 neutral cells grown in the presence of IL-2 only and 




























































































































CD4 cells were cultured under Th2 deviating conditions, in the presence of IL-10 (at different 
concentrations) and addition of 1α,25 [OH]2D3 and dexamethasone (both at 10-7M) from day 7 of 
culture. Cell pellets were obtained at d28 and mRNA was extracted from the cell pellets. Quantitative rT 
–PCT was performed using cDNA created from the mRNA. Th2 or deviated cells were compared to 
pellets from d14 neutral cells grown in the presence of IL-2 only and restimulated at d7 with anti-CD3. 






Cells were cultured under Th2 deviating conditions, in the presence of IL-10 with addition of 1α,25 
[OH]2D3 and dexamethasone (both at 10-7M) from day 7 of culture. MRNA was extracted at day 21 and 







4.2.3  Utilisation of a new microarray strategy to investigate the deviated 
cell phenotype  
 
 
On review of the results relating to expression of genes previously identified to 
be upregulated genes in the original array of calcitriol plus dexamethasone 
induced IL-10+ Treg, the majority of experiments, with the exception of IGF1, 
failed to demonstrate a similar gene profile in the Th2 deviated regulatory cell 
lines and this approach was discontinued. This finding stimulated further work 
on the deviated Th2 cell lines to identify a molecular signature that would 
provide a biomarker(s) and /or account for their regulatory action. A new 
microarray strategy was developed and initiated and the results were 
analysed to identify genes with the highest expression in the regulatory cells, 
as well as the highest level of fold change between the Th2 cell lines and the 
various drug treated conditions. Results for genes of interest were then 




4.2.4 Protocol for selection of cell lines and pooling of cell lines for 
microarray 
 
Th2 cell lines were cultured in deviating conditions as described in the 
previous chapter, some in the presence of IL-10 (Th2 IL-10) with or without 
addition of 1α,25 [OH] D3 plus dexamethasone (both at 10-7 M) from day 14 of 
culture. 
 
mRNA was extracted from cell pellets obtained from 3 individual cell lines 
from each of the conditions for the effector Th2 line and the deviated lines 
resulting in four different cells lines: (i) Th2;(ii) Th2+IL-10; (iii)Th2 with the 






Th2+IL-10 with the addition on day 14 of culture of 1,25 [OH] D3 and 
dexamethasone. The mRNA samples were pooled for each condition and 
cDNA was transcribed using the Ambion WT expression kit (as per protocol). 
Samples were pooled rather than used individually due to constraints in 
availability of the array chip, but it was felt that the data would still be 
representative, and the aim was to then validate the data of interest by q RT-
PCR in remaining material from the four cell lines derived from each of the 
three donors individually. The limitations of this experimental approach are 
addressed further both in the Results section and in the Discussion of this 
chapter. A fifth condition was also added (Th2 d21) in order to facilitate 
normalisation of the array result.  cDNA was labelled and hybridised to the 



















Cells were cultured under Th2 deviating conditions, some in the presence of IL-10 (Th2 IL-10) or with 
addition of 1,25 [OH] D3 plus dexamethasone (both at 10-7  M) from day 14 of culture. 
mRNA was extracted from cell pellets obtained from 3 individual cell lines for each of the conditions 
outlined above. The mRNA samples were pooled for each condition and cDNA was transcribed using 
the Ambion WT expression kit (as per protocol). A control condition was also added (Th2 d21) to ensure 
the validity of the array analysis. cDNA was labelled and hybridised to  the Exon ST array chip 





























4.2.5  mRNA quality control analysis 
 
mRNA samples from cell pellets derived from the individual experiments were 
examined to determine mRNA integrity prior to pooling using the bioanalyzer 















Cells were cultured under Th2 deviating conditions, some in the presence of IL-10 (Th2 IL-10) or with 
addition of 1,25 [OH] D3 plus dexamethasone (both at 10-7  M) from day 14 of culture. 
mRNA was extracted from cell pellets obtained from 3 individual cell lines for each of the conditions 















Table 4 mRNA samples for exon ST microarray 
Sample no Experiment 
no 
Condition Day of culture 
prior to isolation 
1 34 Th2  21 
2 70 Th2 VDIL-10 28 
3 34 Th2 IL-10 28 
4 34 Th2 IL-10 28 
5 34 Th2 VD 28 
6 34 Th2  28 
7 70 Th2 28 
8 70 Th2 21 
9 70 Th2 VD 28 
10 70 Th2 IL-10 28 
11 69 Th2 IL-10 28 
12 37 Th2 VD 28 
13 37 Th2 IL-10 28 
14 37 Th2 VDIL-10 28 
15 37 Th2  28 
16 69 Th2 21 
17 69 Th2 VD 28 
18 69 Th2 28 
19 69 Th2 VDIL-10 28 
 
 4.2.6  Exon ST microarray analysis 
 
The Exon ST microarray of the four cell lines under study was run within the 
Biomedical Research Centre Genomics facility. The microarray results were 
reviewed initially to determine the genes with the highest intensity following 
normalisation. Due to sample constraints (and cost) the samples for each 
condition had to be pooled (as per experimental protocol outlined in Figure 
4.4) rather than used individually. This precluded detailed biocomputational 
analysis to enable determination of genes with statistically significant 
upregulation or downregulation. A pragmatic approach was taken with regard 
to the analysis on this basis. The gene lists were compared to identify the 
greatest fold change in gene expression between the Th2 cell lines and the 
deviated Th2 VDIL-10 cells. The lists were then scrutinised to identify gene 







Evaluation of fold changes between the Th2 VDIL-10 cells and Th2 cell lines 
demonstrated that there were high levels of intensity seen for CYP24A1, an 
enzyme strongly associated with vitamin D metabolism (breaks down the 
active form of vitamin D into its metabolites)107. This provided important 
evidence that the cells had responded appropriately to the 1α,25 [OH]2 D3 
added to cultures as CYP24A1 is known to be highly upregulated by 
1α,25[OH]2D3 and thus provides a positive control for calcitriol actions in 
culture, as a recognised “vitamin D response gene”. However, there was no 
change in fold expression related to cathelicidin, an important vitamin D 
response gene in relation to innate immunity. Both cell lines had similar mean 
intensity. 
 
Legumain (LGMN) is a cysteine protease that cleaves vitamin D from its 
binding protein158. High expression of the gene for legumain was observed in 
the Th2VDIL-10 deviated cell line in comparison to the Th2 cell line (fold 
increase of 32). Legumain not only has a function in vitamin D metabolism 
alone, but has previously been noted to have an influence on phenotype of 
natural (Foxp3+) Treg cells159.  
 
Analysis of fold change in relation to gene ontology demonstrated a number of 
groupings related to biological processes. There were a number of genes 
expressed related to proteolysis. Legumain, as previously described, was 
described within the category of proteolytic genes. A number of granzyme 
genes were also upregulated with an increased fold change between the Th2 
cell lines and the drug deviated cells (even more so than upregulation of IL-
10). Granzymes are serum proteases that induce cell death and have been 
identified in other Treg cell subtypes160,161. 
 
A number of genes related to signal transduction were identified, including 
TAAR6 (polymorphisms of this gene may be associated with asthma), OR4N4 
and OR13C5, members of the olfactory gene receptor family with homology to 






and CD38144. ELOLV4 and ELOLV6 genes were noted, which are genes that 
code for processing of elongated long chain fatty acids. 
 
The gene ontology analysis of Th2 VDIL-10 cells also demonstrated a number 
of genes related to the immune system, such as BTLA 4 (B and T lymphocyte 
factor 4) linked to the B7:CD28 superfamily and PDCD1LG2 (programmed 
cell death 1 ligand 2), one of the ligands for the action of PD-1. PD-L1 has 
been well recognised as a marker for regulatory T cell function, and both PD-1 
and PD-L1 have been reported to be increased in culture by vitamin D144 162 
The effects of PD-L2 on Treg and the lung have been variable and not as 
broadly characterised.  
 
Another focal group of upregulated genes that were identified are involved in 
proteolysis including the granzymes (B and H) and granulysin.  Upregulation 
of genes involved in chemotaxis (CCR1 and CCR10) and angiogenesis 
(VEGF and EPAS) were also noted. CCR10 has previously been reported to 
be increased by vitamin D163. 
 
On analysis of genes that were more highly expressed in Th2VDIL-10 cells as 
opposed to Th2 VD cells (tables 3 and 4), the granzymes again demonstrated 
a high profile. There was also an increase in granulysin expression noted. 
Granulysin was also upregulated in the Th2 VDIL-10 cells, and this enzyme is 
known to co-localise in granules with granzymes and perforin. 
 
A basic heatmap of gene expression was compiled using the pooled data as 
shown in Figure 6 with comparable results to the analyses detailed above. 
Pooling of the RNA samples for the conditions precluded more detailed 
















Cells were cultured under Th2 deviating conditions, some in the presence of IL-10 (Th2 IL-10) or with 
addition of 1α,25 [OH] D3 plus dexamethasone (both at 10-7 M) from day 14 of culture. 
mRNA was extracted from cell pellets obtained from 3 individual cell lines for each of the conditions 
outlined above. The mRNA samples were pooled for each condition and cDNA was transcribed using 
the Ambion WT expression kit (as per protocol). A control condition was also added (Th2 d21) to ensure 
the validity of the array analysis. cDNA was labelled and hybridised to  the Exon ST array chip 
(affymetrix) as per protocol. A Heatmap was generated using bioinformatics computational analysis to 















Table 5 Gene ontology analysis of ExonST microarray results for Th2 VDIL-10 cell lines vs Th2 cell lines at d28 







































































































































































































































mRNA$description$ Fold$change$ Gene$symbol$ mRNA$description$ Fold$change$$
CYP24A1$ Cytochrome*P450*(CYP24A1)* +44.7603062* NEDD8$ Neural*precursor*cell*expressed* +6.03689204 
LGMN$ Legumain* +32.8336447* HPGD$ Hydroxyprostaglandin*dehydrogenase*15H
(NAD)*
+5.99841359 
NRN1$ Neuritin* +21.6101623* GZMB$ Granzyme*B* +5.93951446 
CCR10$ Chemokine*(CHC*motif)*receptor*10* +13.1074124* MYO1B$ Myosin*IB* +5.87731817 
G0S2$ G0/G1switch2* +11.5436775* TXK$ TXK*tyrosine*kinase*(TXK* +5.81728506 
CD79A$ CD79a*molecule,*immunoglobulinH
associated*alpha*
+10.2872467* ILO10$ Interleukin*10* +5.60705414 





+8.69388493* KLRD1$ Killer*cell*lectinHlike*receptor*subfamily*D* +5.23224465 
GZMH$ Granzyme*H* +8.47121555* FKBP5$ FK506*binding*protein*5*(FKBP5)$ +5.15718572 
FAM49A$ family*with*sequence*similarity*49* +8.45545271* CXCR6$ Chemokine*receptor*6* +5.08721476 
CD38$ CD38*molecule* +8.33047639* P2RX5$ Purinergic*receptor*P2X,* +4.98926743 
ELOVL6$ ELOVL*family*member*6* +8.17950195* LOC541472$ Uncharacterised*LOC541472* +4.82116231 
APBB2$ Amyloid*beta*(A4)*precursor*
proteinHbinding,*family*B,**








+6.45867399* OR4N4$ Olfactory*receptor,*family*4* +4.47896689 







Table 7 Gene ontology analysis of Exon ST microarray results for Th2VDIL-10 cell lines vs Th2 VD cell lines at d28 


















































































Table 8 Greatest fold change between Th2 VDIL-10 and Th2 VD
Gene$
symbol$
mRNA$description$ Fold$change$ Gene$symbol$ mRNA$description$ Fold$change$$
GZMB$ Granzyme)B) +39.1891398) RCN1$ reticulocalbin)1,)EF;hand)calcium)binding)
domain)(RCN1)
+3.74488392 
GNLY$ Granulysin) +9.41409884) NRN1$ Neuritin) +3.70788372 
KLRD1$ Killer)cell)lectin;like)receptor)
subfamily)D)
+8.6082919) ITGAX$ Integrin,)alpha)X) +3.70788372 
FAM49A$ Family)with)sequence)similarity)49) +8.41652676) CD9$ CD9)molecule) +3.66725097 
LCE2D$ Late)cornified)envelope)2D) +7.89884658) CCR10$ Chemokine)(C;C)motif))receptor)10) +3.53782822 
SH3BGRL2$ SH3)domain)binding)glutamic)
acid;rich)protein)like)2)
+6.40474441) LOC100130492$ PREDICTED:)Homo)sapiens)misc_RNA) +3.39061505 
ILM10$ Interleukin)10) +5.35726254) PDLIM1$ PDZ)and)LIM)domain)1)(elfin) +3.37747479 
RBMS2$ RNA)binding)motif,)single)
stranded)interacting)protein)2)
+5.31774648) KLRG1$ killer)cell)lectin;like)receptor)subfamily)G) +3.36223136 
GMZH$ granzyme)H)(cathepsin)G;like)2,)
protein)h;CCPX))
+4.81041046) SLAMF7$ SLAM)family)member)7)(SLAMF7$ +3.28212685 
STOM$ stomatin)(STOM),)transcript)
variant)1)
+4.6994014) CHI3L2$ chitinase)3;like)2)(CHI3L2)) +3.23872057 
SCGB1D2$ Secretoglobin,) +4.63276017) AIG1$$ androgen;induced)1)) +3.1989335 
FCRL6$ Fc)receptor;like)6)(FCRL6)) +4.38040278.4) RPL23AP13$ ribosomal)protein)L23a)pseudogene)13) +3.18414272 
PLEK$ pleckstrin$ +4.08897431) DAPK2$ death;associated)protein)kinase)2) +3.17697998 
FGFBP2$ fibroblast)growth)factor)binding)
protein)2)




+3.98528252) NRIP3$ nuclear)receptor)interacting)protein)3) +3.03544493 
RCN1$ reticulocalbin)1,)EF;hand)calcium)
binding)domain)(RCN1)
+3.86530163) HAVCR2$ hepatitis)A)virus)cellular)receptor)2) +2.937712066 
 ! 105 
4.2.7 Validation of microarray by PCR analysis 
 
4.2.7.1 qPCR analysis of mRNA expression of microarray genes involved 
in Treg immune responses (on gene ontology analysis) show trend of 
increased expression in deviated (Th2VDIL-10) cell lines 
 
Human CD45RA+ cells were deviated towards a Th2 profile without or with IL-
10 as previously described. Cultures were restimulated weekly without (Th2; 
Th2IL-10) or with addition of calcitriol plus dexamethasone (both 10-7 M) at 
day 14. mRNA was extracted as described above . The mRNA expression of 
BTLA, LGMN and PDCDLG2 in the individual mRNA samples that were 
ultimately pooled was assessed using real time RT-PCR. 
 
The mRNA analyses demonstrated a trend towards increased expression of 
BTLA4, LGMN and PDCDLG2 in the drug treated cells compared to the Th2 
cell. This was highest in the drug treated cells that were cultured in the 
presence of IL-10 in each of the three donors studied. However, this 
observation was not statistically significant, likely due to small sample size. 
 
 
4.2.7.2 Granzyme expression is highly expressed in VDIL-10 cells 
compared to Th2 cells and Th2 VD cells 
 
The transcriptome results were further interrogated by analysis of granzyme 
gene expression in the different cell lines and this demonstrated highest 















Cells were cultured under Th2 deviating conditions, some in the presence of IL-10  (Th2 IL-10) or with 
addition of 1α,25[OH]2D3 plus dexamethasone (both at 10-7M) from day 14 of culture. Cell pellets were 
obtained at d28 and mRNA was extracted from the cell pellets. Quantitative rT-PCR was performed 
using cDNA created from the mRNA . Data represents mean + SEM of 3 experiments performed using 













Cells were cultured under Th2 deviating conditions , some in the presence of IL-10  (Th2 IL-10) or with 
addition of 1α,25[OH]2D3 plus dexamethasone (both at 10-7M) from day 14 of culture. Cell pellets were 
obtained at d28 and mRNA was extracted from the cell pellets. Quantitative rT-PCR was performed 
using cDNA created from the mRNA. Data represents mean + SEM of 3 experiments. performed using 
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4.3 Discussion 
 
Calcitriol has significant effects on genes related to both innate and adaptive 
immunity, and a large number of genes that are involved in innate immunity 
pathways were expressed in preliminary work from the lab performed on 
freshly isolated peripheral blood CD4 cells treated with calcitriol and 
dexamethasone, including TLR9, TLR2 and SERPINA. On review of mRNA 
expression in Th2 cells deviated with drugs, decreased expression of these 
genes was noted on qPCR analysis of mRNA expression in the Th2 cell lines 
alone and also in the Th2 cell lines deviated with drugs (with the exception of 
TLR2). One possible explanation for this may be the cytokine environment 
surrounding the cells.  The Th2 cell lines were driven by addition of 
exogenous IL-4 to culture, and IL-4 can suppress some TLR responses, 
including TLR9164,165. SERPINA codes for one of the serpin proteins, which 
are serum protease inhibitors. Serpin activity has been characterised in the 
context of alpha 1 antitrypsin deficiency and chronic obstructive pulmonary 
disease, involving excessive neutrophil elastase activity. The role of serpins in 
T lymphocytes is not very well defined, and the data from my experiments do 
not show a sufficiently strong trend to allow conclusions to be made in relation 
to the regulation or any potential function of serpin expression by T cells. 
 Similarly, although IGF-1 mRNA expression was increased in the Th2VDIL-
10 deviated cultures from 2 donors the data are too preliminary to draw any 
strong conclusions. 
 
The transcriptome analysis of the Exon ST microarray revealed pathways that 
may be of significance in relation to the function of the deviated regulatory 
cells. On review of the transcription factors and cytokine analysis described in 
the previous chapter, the expression of GATA3 was reduced in the deviated 
cells in comparison to the effector cells, although not completely abrogated, 
with a moderate fold change noted. There was reduced mean expression of 
RORC in all cell lines in comparison with the Th2 cytokine associated 
transcription factors. The same effect was seen for TBX21 (T bet). Variability 
in Foxp3 mean intensity levels between conditions was seen in parallel with 
the mRNA findings described in the previous chapter, i.e. higher in VD than 
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VDIL-10 or Th2. Reassuringly IL-10 analysis showed high levels and high fold 
change in the VDIL-10 group compared to Th2 and VD groups. 
 
The transcriptome analysis of the Exon ST microarray revealed pathways that 
may be of significance in relation to the function of the deviated regulatory 
cells, with the increased expression, validated through PCR, of a number of 
genes related to immune function and also genes related to cytotoxic cell 
killing.  
 
BTLA (B and T lymphocyte activation factor) was evaluated as well as 
PDCDLG2 the gene for PD ligand 2, one of the ligands that binds PD-1, a 
marker of Treg function and immunosuppression. BTLA is an inhibitory 
receptor that has homology with CTLA-4 and PD-1 166 and binds HVEM (the 
TNF receptor herpesvirus entry mediator). PD-L2 is one of the ligands for the 
PD-1 molecule and belongs to the B7:CD28 superfamily of ligands. PD-L2 
predominantly acts via PD-1 but may have anti-inflammatory actions that are 
PD-1 independent, preventing eosinophilia167 and promoting respiratory 
tolerance168. Fold change of gene expression between Th2VDIL-10 and Th2 
cell lines was notable, and there was higher expression seen in the VDIL-10 
cells on validation of mRNA, although the increase did not achieve statistical 
significance. Further biological replicates would need to be studied to 
determine whether this represents a reproducible trend, and whether these 
molecules are implicated in the suppressive function of the deviated  Th2 
cells. 
 
The transcriptome analysis of the Exon ST microarray revealed pathways that 
may be of significance in relation to the function of the deviated regulatory 
cells, with the increased expression, validated through PCR, of certain 
granzymes (B, H and K).  The highest level of granzyme expression seen 
related to granzyme H, although previous authors have noted a link between 
IL-10 and granzyme B expression. Human IL-10 Tregs that suppress Th1 
responses have been noted to express granzyme B160,169. Granzyme B 
knock-out mice have impaired natural Treg function170. Tregs regulate 
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immune responses to viral infection in the lung via a granzyme B mechanism 
161. 
 
Granzyme B acts via cell-to-cell contact with effector T cells 147 . Its action is 
typically facilitated through the action of perforin to enable transfer to the cell 
targeted for lysis. Tr1s may also kill myeloid APCs through a granzyme B 
mediated process leading to bystander suppression 147.  Granzyme B cell 
killing is classically caspase 3 dependent although it may also occur 
independently of caspase-3 147.  The action of Granzyme H is also caspase 
independent 171. Thus Th2 cells deviated with calcitriol, dexamethasone and 
exogenous IL-10 appear to possess more than one inhibitory mechanism that 
can dampen down unwanted immune responses associated with allergic 
disease. A priority for future work would be to validate the protein expression 
of these various molecules by flow cytometry and/or antibody capture assays, 
and ideally to investigate whether the deviated Th2 cells used these 
molecules to exert their inhibitory activity. 
 
The last experimental aim of the chapter was to validate the mRNA analysis 
by exploring the action of postulated genes/proteins by blocking studies in 
vivo. From the chapter outlined above, a robust target would appear to be 
granzyme activity, given that there was high fold change between Th2VDIL-10 
and Th2, as well as Th2VDIL-10 and Th2VD cells. Time available precluded 
further work on mechanistic function of the granzymes, but this would be a 
central focus for this work to be progressed further.  
 
Experimental approaches would initially include visualisation of granzyme 
protein expression by flow cytometry161 and/or microscopy. However, the 
major priority of future studies would centre around assessing whether 
granzymes play a role in the inhibitory function of deviated Th2 cells. 
Approaches would include: 
 
i. Assessment of cell death using traditional methods such as annexin 
staining to denote apoptosis and propriidium iodide to denote 
necrosis, in combination with flow cytometry.  
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ii. Inhibition of specific granzyme activity using blockers such as 
compound 20172, which blocks granzyme B function. 
Bioluminescence assays could also be used that would involve the 
use of luciferase biosensors linked to specific granzyme cleavage 
sites173, that would be activated by granzyme in target cells and 
thereby monitor specific granzyme activity in co-culture.   
 
iii. Measuring downstream activity to determine if regulatory activity is 
caspase-dependent by assessing the level of active caspase 3 by 
flow cytometry174, or granzyme interactions that are caspase 
independent, such as the rate of bid (proteolytic enzyme) cleavage, 
or the effect on cytochrome c. In is noteworthy that granzyme H 












Steroid insensitivity and Th17 cytokines - assessment of IL-17 
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5.1  Introduction 
 
The previous chapters have described the plasticity and stability of Th2 cell 
phenotypes.  Typically asthmatic and allergic responses are characterised by 
early and late phase responses dominated by Th2 cytokines71. Whilst the 
majority of patients respond favourably to steroids for control of their clinical 
symptoms in association with downregulation of the Th2 response, there 
exists a significant cohort of patients with significant morbidity related to their 
asthma who exhibit insensitivity, or resistance to steroids177. The previous 
chapters studied the capacity of steroids, together with the steroid response 
modifier, vitamin D131, to influence the Th2 immune profile towards a more 
immunoregulatory profile. Alternative T cell pathways may influence steroid 
insensitivity, in particular Th17 mediated pathways178. 
 
The T helper cell family has expanded with the discovery of Th17 cells. These 
cells are differentiated in the presence of IL-6, IL-21 and IL-23 in humans, and 
they are thought to play a role in defence against extracellular pathogens 
such as fungal organisms and extracellular bacteria at mucosal sites such as 
the airways179.  The release of Th17 cytokines promotes expression of 
proteins that are responsible for innate defences such as defensins9. Th17 
cells co-express IL-22, although work has demonstrated another category of 
CD4+ Th22 cells with a distinct cytokine and profile, that express IL-22 
independently of Th17 cells and may be responsible for modulating pathology 
in dermatological disease180. Th17 cells may play a role in combating 
infections with extracellular pathogens, but uncontrolled expression of IL-17 
may contribute to autoimmune diseases such as rheumatoid arthritis and 
ulcerative colitis.  
 
IL-17 expressing cells have been noted in mild as well as severe 
asthma181,182, but studies suggest that IL-17 positive cells may contribute 
towards a more severe asthma phenotype. IL-17+ve cells have been noted in 
the bronchial tissue of asthmatics with increasing frequency seen in severe 
disease183,184, in addition to increasing levels of IL-17 mRNA in sputum185. 
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One group demonstrated that increased levels of IL-17 in serum correlated 
with asthma severity186.  
 
Studies have been performed to try and identify inflammatory phenotypes 
within cohorts of patients with severe asthma. Steroid insensitivity in some 
cases may be associated with inflammatory profiles that lean towards 
neutrophilic rather than eosinophilic inflammation177. IL-17 production can be 
associated with a steroid-resistant phenotype187, with evidence in humans that 
it may promote neutrophilia in the airways188 185.   
 
Earlier bronchial studies had suggested that eosinophils could be a possible 
source of IL-17 in the bronchi, at least in mild asthmatics182, with increased IL-
17 levels seen in the presence of significant sputum eosinophilia in patients 
with less severe disease, but other authors have noted that the T cells are the 
source of IL-17, particularly in more severe asthmatics185. IL-17 production 
may also contribute to remodelling as it promotes the proliferation of human 
fibrocytes189. Mechanistic studies suggest that Th17 cell phenotypes can 
skew towards a more pathogenic phenotype associated with IFN gamma 
production190, with certain pathogens promoting a Th17 and neutrophil 
response within asthmatic airways191. This response may be amenable to 
macrolide treatment, at least in animal models192. 
 
Calcitriol has varying effects on Th2 cytokines – it may augment Th2 cytokine 
production in CD4 culture120,193 and previous work has demonstrated that it 
augments IL-10 production in CD4+ T cells131.  
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Hypothesis 
 
In the previous experimental chapters my work identified a potential role of 
vitamin D plus dexamethasone (and IL-10) in beneficially modifying Th2 
responses in the context of allergy/asthma. However additional/more recent 
work highlights a role for Th17 cells in asthma pathology, of interest and 
importance since Th17 responses are proposed to be of important in steroid 
refractory disease. The hypothesis to be investigated here, therefore, is that 
Th17 responses will show a distinct profile of modulation by dexamethasone 
plus calcitriol in comparison to the previously observed and reported effects 
on Th2 responses.  
 
Experimental aims  
 
The aims of the experiments described in this chapter were as follows: 
 
• To assess the effects of dexamethasone on Th17 cytokines. 
• To assess the impact of different T cell stimulation conditions on 
production of Th17 cytokines in relation to dexamethasone, with anti- 
CD3 and low dose IL-2 initially, and then against the more powerful 
stimulus of anti-CD3 plus anti-CD28; followed by investigation of Th17 
cytokine production in the presence or absence of IL-4 within culture. 
• To assess the effect of vitamin D, in the presence or absence of 
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5.2 Results  
 
5.2.1 Dexamethasone maintains CD4+ IL-17+ and IL-22 + populations, 
and may promote inflammatory IL-17A responses.  
 
CD4+ T cells were isolated from peripheral blood mononuclear cells using 
magnetic beads and cultured for 7 days. TCR stimulation was achieved by 
anti-CD3 stimulation alone without the use of anti-CD28 or antigen presenting 
cells. Cells were cultured in the presence of low dose IL-2, with and without 









Top figure. CD4+ T cells were isolated with magnetic beads and cultured for 7 days with αCD3 and IL-2 
with dexamethasone 10-7M (dex) or without (neutral). Intracellular cytokine staining was performed 
following stimulus with PMA and ionomycin at day 7. Representative experiment of 3 shown 
Bottom figure.  Analysis of staining – review of total versus double positive cells. CD4+ T cells were 
isolated with beads and cultured for 7 days with αCD3 and IL-2 with or without dexamethasone at 10-7M 
from day 0. Intracellular cytokine staining analysis was performed at day 7 following stimulus with PMA 
and ionomycin. Left – total IL-17A+ vs. IL-17A+IL-10+ cell frequency, n=3, 3 individual donors. Right –
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Analysis of the cell populations demonstrated that cultures containing 
dexamethasone produced more IL-17+ and IL-22+ cells than the neutral 
condition (absence of dexamethasone; Figure 5.1), with almost double the 
number of single positive IL-17A+ cells seen via intracellular cytokine staining, 
but also an increase in IL-17A+IL-22+ populations, in addition to IL-22+ single 
populations.  However, in the small number of experiments performed (n=3) 
this did not achieve statistical significance and is therefore best described as 
the failure of dexamethasone to inhibit the IL-17A response or a potentially a 
trend to enhance this response. Comparable levels of IL-17+ and IL-22+ 
secretion were seen when analysing cytokines via ELISA (Figure 5.2), in 
cultures irrespective of whether dexamethasone was present in culture. On 
further review of the cytokine profile, culture of the CD4+ T cells with 
dexamethasone showed a trend for an increase in the proportion of IL-
17A+IFNγ+ cells, and IL-17+IL-10+ cells, but these were proportionately fewer 
than the single positives (Figure 5.1). The level of single positive IL-10+ve 






CD4+ T cells were isolated with magnetic beads and cultured for 7 days with anti-CD3 (αCD3) and IL-2 
with or without dexamethasone (dex) at 10-7M from day 0. Cell supernatants were obtained and an 
ELISA was performed to assess cytokine levels at day 7. N=3, three  individual donors, data = mean + 
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5.2.2 Effect of stronger T cells stimulation on Th17 responses  
 
The maintenance, and enhancement of IL-10 expression with dexamethasone 
may reflect the effect of low dose IL-2, and a mild T cell growth stimulus of 
CD3 alone, in the absence of αCD28 stimulation. although this can also 
promote IL-17A expression, with the generation of a mixed population of cells 
co-expressing IL-17A plus IFNγ, IL-17A plus IL-22 and IL-17A plus IL-10 
(Figure 5.1). The next set of experiments aimed to assess the effect of a more 
powerful T cell stimulus with the addition of costimulatory anti-CD28 in culture 






CD4+ T cells were isolated with magnetic beads and cultured for 7 days with anti-CD3 and IL-2 with or 
without anti cd28, or dexamethasone 10-7M (dex) from day 0. Cell culture supernatants were obtained 
and an ELISA was performed to assess cytokine levels at day 7. Data = mean of 3 experiments (3 
individual donors) + SEM, *p<0.05, one way ANOVA.  
 
After 7 days of culture it was evident that total IL-17 and IL-22 production was 
increased with the stronger stimulus of anti CD3/anti CD28 as compared to 
anti CD3/low dose IL-2 in ‘neutral’ cultures with receptor stimulation alone and 
without any dexamethasone (Figure 5.4). Interestingly the level of IL-17A 
production was not maintained with dexamethasone when cells were cultured 
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previously seen with anti-CD3 plus low dose IL-2 stimulus.  The same effect 
was seen for IL-22 synthesis after 7 days of culture (Figure 5.4). 
 
 5.2.3. The frequency of CD4+ IL-17+ and IL-22 + populations is reduced 
by the presence of calcitriol in cell culture. 
 
Vitamin D modulates a number of cytokines with variable effects. It may 
enhance Th2 cytokines before diminishing their production by T cells in long-
term cultures as well as enhancing production of more regulatory cytokines 
such as IL-1039,120,193. The next set of experiments was performed to assess 
the effect of vitamin D on IL-17A when used alone, and to assess the effect of 
this drug in CD4+ cultures in vitro in contrast to, and in combination with, 
dexamethasone. 
  





CD4+ T cells were isolated with magnetic beads and cultured for 7 days with anti-CD3 and IL-2 with 
calcitriol at 10-7M (vit) or without (Neutral) from day 0. Intracellular cytokine staining was performed 
following stimulus with PMA and ionomycin at day 7. Representative plot from 3 experiments. 
 
CD4+ cells were cultured for 7 days in the presence of anti-CD3, and IL-2 with 
and without calcitriol. There was a marked reduction in most of the cytokines 
produced at day 7 in comparison to the neutral condition, with marked 
attenuation of the IL-17A and IL-22 responses. The IFNγ response was 
reduced but this was less profound. There was preservation of the IL-10 
response (Figure 5.5). 
   
 
 





CD4+ T cells were isolated with magnetic beads and cultured for 7 days with anti-CD3 and IL-2 with or 
without calcitriol (v) and/or dexamethasone (d; vd) at 10-7M from day 0.  The supernatant from cells 
isolated at day 7 was analysed using ELISA. Intracellular staining was performed following stimulus of 
the cells with PMA and ionomycin at day 7. Data represents mean of 3 experiments (3 individual 
donors) + SEM, *P<0.05, p<0.01 one way ANOVA 
 
The ELISA data (Figure 5.6) showed a marked decrease in IL-17A and IL-22 
cytokine levels with the addition of calcitriol in vitro. Dexamethasone alone 
failed to significantly alter IL-17A or IL_22 secretion under these culture 
conditions. On analysis of the combined effects of the drugs, it was noted that 
the diminution in IL-17A and IL-22 responses was maintained when calcitriol 
was used in combination with dexamethasone, thus the inhibitory effects of 
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5.2.4. The Th2 cytokine, IL-4 diminishes CD4+ IL-17+ cell responses to 
dexamethasone in culture 
 
The characteristic cytokine that defines and promulgates the Th2 phenotype 
is IL-4, with reciprocal downregulation of Th1 responses. The CD4+ culture 
system outlined above was interrogated to identify if IL-4 exhibited any 






























CD4+ T cells were isolated with magnetic beads and cultured for 7 days with anti-CD3, IL-4 and IL-2 
with or without dexamethasone 10-7M from day 0.  The cell supernatants were isolated at day 7 and 
analysed using ELISA. Results for two separate donors shown 
 
Experiments demonstrated that the addition of IL-4 to the cell culture reduced 
the levels of IL-17A and IL-22 overall in the presence of the neutral condition 
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(stimulus with anti-CD3 alone in the presence of IL-2). The previous 
observation seen with dexamethasone in culture, namely maintenance of IL-
17A and IL-22 levels at day 7 of culture of CD4s in the presence of 
dexamethasone was not sustained and levels also decreased (Figure 5.7) in 
the presence of IL-4, although the experiments were performed for only two 
donors and therefore it would be difficult to draw very strong conclusions from 
the data. 
 
5.2.5. Pam3 Cys, a TLR2 agonist, does not augment IL-17A responses in 
the presence of dexamethasone 
 
A recent paper 194 indicated that stimulation of the TLR2 receptor on CD4+ T 
cells, in a mouse model may augment IL-17A responses. This was proposed 
to facilitate the augmentation of IL-17A and IL-22 responses that promote 
innate immunity. Work previously performed in our lab demonstrated that the 
addition of calcitriol and dexamethasone to CD4+ T cell culture augments the 
expression of the TLR2 receptor  and further work demonstrated that 
dexamethasone alone increases TLR2 expression (unpublished data). The 
next set of experiments was performed to assess if the addition of a TLR2 
agonist, Pam3Cys, to culture of human CD4+ T cells with dexamethasone 





















CD4+ T cells were isolated with magnetic beads and cultured for 7 days with anti-CD3, and IL-2 with or 
without dexamethasone 10-7 M (d) and/or Pam3Cys from day 0. Intracellular cytokine staining analysis 
was performed at day 7 following stimulation with PMA and ionomycin. A– IL-17A; B IL-17+IL-22+  cells. 
C – IL22+IL17- cells. Data from two separate donors shown.  
   
 
 Analysis of IL-17A levels by intracellular staining showed that IL-17A levels 
were reduced in the presence of Pam3Cys and the TLR2 agonist failed to 
maintain or enhance IL-17A responses  in culture with dexamethasone. A 
similar pattern was observed when analysing the IL-22+ single positive 
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5.2.6.  Assessment of cytokine production at earlier timepoints suggest 
that higher levels of IL-17A are seen with vitamin D rather than 
dexamethasone at day 3 compared to day 7 
 
The kinetics of IL-17 responses were further investigated by assessing the 
profile of ELISA data for cytokines produced at day 3 of culture with anti-CD3 
(with and without drugs, and also with and without IL-4). Interestingly, in 
contrast to the high levels of IL-17 seen in culture with dexamethasone at the 
day 7 timepoint, (Figures 5.1 and 5.2), higher levels of IL-17 and IL-22 were 
seen in the presence of calcitriol at day 3 than with dexamethasone(Figure 
5.9). All levels were reduced in the presence of IL-4 (Figure 5.9B and 5.10B) 






























CD4+ T cells were isolated with magnetic beads and cultured for 3 days with anti-CD3 (acd3), IL-4 (il4)  
and IL-2 with or without dexamethasone 10-7M (d) and/or calcitriol (v; vd) as indicated.  The supernatant 
from cells isolated at day 3 was isolated and analysed using ELISA. A – IL-17 without and B IL-17 with 
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CD4+ T cells were isolated with magnetic beads and cultured for 3 days with anti-CD3 (acd3), IL-4 (il4) 
and IL-2 with or without dexamethasone 10-7M (d) and/or calcitriol (v; vd) as indicated.  The supernatant 
from cells isolated at day 3 was isolated and analysed using ELISA . IL-22 without (A) and (B) with IL-4 
addition to culture. Data from two individual donors is shown. 
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5.3. Discussion 
 
This chapter assesses the capacity of peripheral blood CD4+ T cells to 
synthesize Th17-associated cytokines, and the maintenance of IL-17A 
production in the presence of glucocorticoids in culture. 
 
The experiments were performed on CD4+ T cells freshly isolated from 
PBMCs and experiments performed in vitro showed that after 7 days of 
culture with a moderate strength T cell stimulus, in the presence of IL-2, that 
dexamethasone, a glucocorticoid maintained the IL-17+ population. It is likely, 
given the starting population that the majority of the IL-17+ cells were 
CD45RO+ rather than naïve CD4+ Tcells195, an observation that has 
subsequently been confirmed by others in the lab (E Mann, unpublished 
data). Dexamethasone also maintained the IL-22+ve population in addition to 
the total IL-17+ve population and there was also a trend towards an increase 
in the IL-17+IL-22+ population.  
 
The presence of other cytokine double positive populations within the IL-
17+ve population was also investigated, as different double positive 
populations have been postulated to show either pathogenic or more 
regulatory effects. IL-17+IFNγ+ cells have been identified in murine studies of 
experimental autoimmune encephalomyelitis5 and have also been identified in 
humans196 where they may cause pathology such as inflammatory bowel 
disease197. Conversely, double positive cells may have a more regulatory 
phenotype with an IL-17+IL-10+profile.  
 
On review of the cytokine profile of the double positive cells seen on culture of 
human CD4+ T cells with anti-CD3 with or without dexamethasone, the use of 
dexamethasone in vitro led to expression of both IL-17+IFNγ+ and IL-17+IL-
10+ve in equal measure, which indicates that this drug may promote 
inflammatory responses in addition to the anti-inflammatory actions that are 
seen in treatment of autoimmune disease. The persistence of a putatively 
pathogenic population in culture with dexamethasone may account for 
subsequent resistance to glucocorticoid treatment in chronic disease. 
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However, the proposed pathogenic or regulatory function of these populations 
was not assessed, and future work to address this would be important to 
understand the relevance of these observations. This would include the use of 
more advanced multicolour flow cytometry to better define the IL17+ve 
populations, isolation of the different cell populations by cell sorting and 
coculture experiments with autologous cells to assess proliferation and 
cytotoxicity.  
 
The effect of a stronger stimulus in culture, namely by combining anti-CD3 
with anti-CD28 costimulation, was compared to stimulation with anti-CD3 and 
IL-2. Results from experiments performed with anti-CD28 in vitro 
demonstrated a higher level of IL-17 production overall in the neutral condition 
compared to anti-CD3 alone. However, the elevation in IL-17 levels was not 
maintained in the presence of dexamethasone when anti CD28 was also 
present in culture, an observation that has again subsequently been validated 
by others in the Hawrylowicz lab. This may reflect a lack of cytokines that 
promote the persistence of the Th17 phenotype in the presence of stronger 
stimulation, such as IL-1β and IL-239.  It is notable that both the anti-CD3 and 
anti-CD28 experiments were performed in the presence of low dose IL-2, 
which appears to be required for persistence of IL-17 secretion, although this 
effect is not seen at the onset of culture, and influences phenotype from day 3 
and onward195. One further step that would help to progress investigation of 
the influence of dexamethasone at this stage would have been separate 
experiments with and without IL-2 at early and later time points to assess any 
differential effect.  
 
The effect of calcitriol was reviewed at two different time points, both at day 3 
and day 7. By day 7 of culture with anti-CD3 and IL-2, IL-17 and IL-22 
production in the CD4+ T cells was abrogated, with preservation of IL-10 
secretion. Previous work has shown that the addition of calcitriol to 
dexamethasone promotes an IL-10 phenotype and the use of calcitriol and 
dexamethasone in tandem did not lead to an increase in IL-17 secretion, 
therefore promoting a more regulatory cytokine pattern. The reduction in IL-17 
and IL-22 production by calcitriol is not seen at the earlier timepoint of day 3. 
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The reason for this was not ascertained in the present study. However, since 
both calcitriol and dexamethasone are known to reduce cell proliferation, 
assessment of cell proliferation using a dye such as CellTraceViolet would 
allow analysis of whether the increase of Th17 cytokine expressing T cells 
seen in the presence of dexamethasone reflected a preferential expansion of 
this population as seems likely, and might reflect the relatively late time point 
at which this effect was observed.  
 
The effect of a TLR2 ligand was studied as it has been reported to augment 
IL-17 responses when CD4+ T cells are stimulated directly via this receptor 
194.In the current experiments with Pam3Cys, a TLR agonist, did not lead to 
an increase in IL-17A production in the presence or absence of 
dexamethasone. Other studies looking at the effect of Pam3Cys in human 
systems have noted that stimulation of Pam3cys augments IL-17 production 
via the action of dendritic cells that produce cytokines such as IL-6 and IL-1β 
that stimulate CD4+ cells towards production of Th17 cytokines 195,198. 
Dendritic cells may also produce these cytokines in response to TLR4 stimuli 
(LPS) and imidazoquinolone, a TLR8 agonist195. A further extension of this 
work would be to assess the response to drugs in a system that involved 
APCs and the different TLR stimuli, which would have relevance for the lung 
in exposure to different antimicrobial challenges. 
 
This work was commenced as a logical extension to the Th2 study as Th2 
and Th17 cells are associated with different phenotypes of asthmatic disease, 
and the potental for calcitriol and dexamethasone to have differential effects 
was not anticipated. More detailed cytokine secretion studies would have 
been of benefit  to address the time course of the changes effected by the 
addition of drugs. Although the current body of work is in many ways 
incomplete this body of work then merged and was superceded by other 
ongoing studies in the lab after identifying significant differences in IL-17A in 
steroid sensitive  vs steroid-resistant patients 199  and that an in vivo correlate 
between inhaled steroid dose and IL-17A levels in culture were positively 
correlated.  
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There is a large body of evidence that outlines the significant burden of 
asthma and allergic disease in the UK and worldwide. These conditions cause 
significant impairment in quality of life on a personal level, but also to the 
general population through time off school or work with subsequent loss of 
productivity in part due to their very high prevalence. In the UK, it is estimated 
that around 5.4 million people are currently receiving treatment for asthma i.e. 
one in every 12 adults and one in every 11 children.  
 
A number of therapies are available to treat allergic disease, the majority of 
which control disease symptoms but do not cure or prevent long term disease 
progression. However, the long term immunological goal has always been to 
identify ways to cure. A number of biological therapies have been investigated 
including anti-IgE and a number of strategies developed to target cytokines 
implicated in disease pathogenesis. However, these have largely been 
disappointing and none suggest that individually that they will provide a long 
term practical strategy to afford long term relief of disease symptoms. What 
they have highlighted is the heterogeneity of human allergic and asthmatic 
disease, and that the quest for improving therapeutic strategies needs to take 
this diversity into account.  A clear example of this are studies of the 
monoclonal antibody Lebrikizumab (anti-IL-13) which only improved lung 
function in patients with a periostin-high asthma phenotype, an observation 
that encouragingly originated in studies of molecular phenotype84.  
 
Allergy, uniquely, has had an antigen-specific treatment in use, pioneered 
over 100 years ago i.e. allergen immunotherapy; however this is not 
commonly advocated for allergic asthma in the UK, although widely used 
overseas, as it can poses significant risks and is not unilaterally effective. It is 
generally assumed, particularly in studies of allergic rhinitis, to require a 
prolonged period of treatment to gain maximal efficiency, which can make it 
cumbersome to administer.  
 
A number of strategies are being studied to improve both the safety and 
efficacy of allergen IT. These include modified allergens (e.g. peptides, 
chemically modified allergens), different routes of delivery, as a combination 
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therapy for example with anti IgE, and adjuvants that may enhance the 
capacity to promote regulatory pathways such as IL-10 since good evidence 
exists that where IT is effective this is associated with increased IL-10 
synthesis within the monocyte, B and T cell compartments. 
 
There has been a lot of evolving work in the past decade, reflecting the 
complexity of T cell plasticity, with additional T cell subsets described that are 
proposed to play a role in allergic and asthmatic disease beyond the original 
Th2 paradigm187 as well as evidence for the potential plasticity between T cell 
subsets, including both regulatory T cells and effector subsets. Allergen 
immunotherapy, generally used to target Th2-mediated allergic disease, may 
lead to deviation of a Th2 response towards a more regulatory phenotype140. 
The broader remit of the work presented here aimed to investigate 
mechanisms that might improve the safety and efficacy of allergen IT, directed 
particularly at Th2 mediated allergic disease. It sought to build on earlier 
findings within the scientific field, in part highlighted above and discussed 
within this thesis, and from our lab that steroids with vitamin D promote IL-10 
synthesis. The work was done to establish if deviation of existing Th2 
responses associated with disease and effective IT could be enhanced by 
combining with dexamethasone and vitamin D. The work was subsequently 
extended to identify the effects of vitamin D and dexamethasone on Th17 
responses, associated with a distinct phenotype of severe asthma. 
 
The major findings of this work demonstrated that Th2 cells that were 
deviated with calcitriol and dexamethasone have a similar profile to Tr1 cells. 
There is a requirement for exogenous IL-10 but this does not appear to be the 
mechanism for suppression as this action is not blocked by anti IL-10R (and is 
not affected by the action of anti TGFb or anti CTLA4). One caveat to this 
conclusion however, is that the blocking reagents used in this study were only 
tested singly and not in combination. The deviated cells do not exhibit the 
phenotype of natural T reg as they exhibit low Foxp3 expression in 
combination with high IL-10 expression. A pragmatic analysis of the ExonST 
microarray demonstrated upregulation of genes related to granzyme activity, 
which may be a putative mechanism for the action of the suppressor cells and 
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account for ‘regulatory cell’ activity. It has been demonstrated that regulatory 
cells act through the action of granzyme in other Treg systems, such as those 
mediated by the action of complement43, and may also have a role in 
mediating responses to viral infection, associated with an IL10 response 
mediated by AhR161. 
   
The manipulation of Th2 cells to deviate towards a regulatory profile may 
mean that the use of these drugs is an alternative to standard glucocorticoid 
therapy and also may be of benefit in immunotherapy to augment accelerate 
the conversion of Th2 responses towards an immunoregulatory profile. One 
major caveat is that we have still yet to understand the full capacity and 
plasticity of T cell phenotypes and we must ensure that the regulatory cells 
maintain their beneficial phenotype without conversion or rather reversion to 
the previous harmful Th2 effector phenotypes, which may be harmful.  
 
These experimental studies utilised the drug combination of the glucocorticoid 
dexamethasone, together with the active form of vitamin D3, 1α,25-
dihydroxyvitamin D3 or calcitriol, to effect deviation of a disease-promoting 
Th2 profile towards a more regulatory IL-10+ phenotype. A more acceptable 
and practical therapeutic approach to adopt in patients might be to restore 
vitamin D sufficiency through supplementation of those individuals prior to and 
during immunotherapy, given the high prevalence of vitamin D deficiency and 
insufficiency. Supplementation with 25-hydroxyvitamin D3, as opposed to 
1α,25-dihydroxyvitamin D3, is likely to be more acceptable, having a longer 
half life and with fewer potential safety concerns. Furthermore, the capacity of 
vitamin D to promote and maintain multiple regulatory pathways, including IL-
10, is arguably a good conceptual basis for such a strategy. Counter 
arguments to such an approach include experimental evidence that vitamin D 
can enhance Th2 responses, although as discussed within this thesis, 
paradoxically an inverse correlation between vitamin D status and parameters 
of allergic disease exists122,123, and this may therefore not reflect such a 
serious concern. The concept of combining vitamin D treatment with allergen 
immunotherapy is being increasingly explored in animal models200-202 which in 
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general provide positive data to support this strategy together with a few early 
studies in humans, which provide some supporting data203,204.  
 
Calcitriol was also found to have additional effects on Th17 cytokine 
production even in the presence of dexamethasone, with a broader 
implication for the use of this drug in treatment of (glucocorticoid resistant) 
allergic disease. The lab subsequently went on to show a comparable 
modulation of Th17 responses by calcitriol in vivo205. The messages from that 
study are a validation of a number of years work from the lab showing that 
steroids upregulate IL-10, that this response is impaired in steroid resistance 
and can be restored with calcitriol. However the observation made here and 
extended through other studies in the lab, that steroids fail to inhibit and can 
increase IL-17A, an effect that is more marked in steroid refractory asthma, is 
noteworthy. We have hypothesised that the capacity of steroids to maintain an 
IL-17 response will play an important role in maintaining protection to mucosal 
pathogens in mild/moderate disease, although clearly as indicated by both our 
own and independent work an over exuberant IL-17 response is likely to be 
detrimental in severe disease. What alters the balance between a putatively 
protective IL-17 response versus one assocated with disease pathology is 
unknown. Furthermore whether protective and detrimental IL-17/Th17 
responses differ qualitatively, as alluded to in the present studies and other 
work published form our lab199 remains to be fully investigated and 
determined.  Importantly evidence from work performed in the lab following on 
from this thesis shows that vitamin D/calcitriol in culture, and following 
ingestion of calcitriol by steroid- resistant patients inhibits the Th17 response 
even in steroid-resistant patients199.  
 
Further work to try and augment the experiments outlined above should aim 
to look to generate more allergen specific modes of action and attempt to 
delineate and refine the mechanisms of action of the deviation towards 
regulatory responses. 
 
Initially the aim would be to assess the capacity to develop a more allergen- 
specific model of the Th2 cell lines studied here. Multicolour flow cytometry 
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has progressed tremendously and this would enable re-evaluation of 
strategies to establish markers to identify the cell phenotype e.g. CD127, 
LAG3, CD39 etc. This could be used alongside techniques such as HLA class 
II peptide tetramers206 to stain allergen specific T cells, as well as intracellular 
cytokine staining to evaluate allergen specificity both experimentally in culture 
and animal models, but also ideally in patients207. 
 
Cells deviated in the presence of calcitriol and dexamethasone could be 
investigated to assess stability of the deviated Th2 cells after withdrawal of 
promoting cytokines over a more prolonged period than that required for the 
CFSE suppression assay. This capacity for plasticity should be tested in 
relation to the presence of other stimuli including allergens and Th17 stimuli to 
assess their capacity to maintain their phenotype and prevent transformation 
to Th17 phenotypes208. Translation of these important issues directly into 
patient based studies is highly desirable and is now becoming realistic based 
on ongoing technical advances such as those noted above. 
 
In order to explore mechanism of action of the new deviated cells it would be 
imperative to examine the capacity if the cells to utilise granzyme and perforin 
pathways and identify if this is the true mechanism that underlies 
regulation171,209.  
  
The Exon ST array could be examined further to identify other genes of   
interest that would assist in definition of the Treg phenotype. Ideally in order to 
facilitate analysis, a greater number of arrays would be required for each cell 
line so that biocomputational review can take place. Whilst a number of 
limitations exist in the present study, gene transcriptional arrays studies have 
proved highly successful in identifying new gene targets and biomarkers in 
allergic disease72, and the current work has opened up new potential avenues 
for further investigation. 
 
In conclusion, the work outlined above demonstrates the capacity for 
immunomodulation using vitamin D3 to combat immune mediated disease 
and provides hope that a strategy involving treatment with vitamin D3 carries 
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the potential for improved treatment alone or in concert with other forms of 
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